| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology | ||
Phase 1b data readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Rigel Pharmaceuticals, Inc.$42.55
-1.66 (-3.79%)
C 56Pipeline Score Fair Value Pharma · Commercial
Market Cap
536.75 M
EPS
20.07
P/E Ratio
1.55 $
Value Trade
12.67 M
SEC Financials
Q1 2026Dilution Risk
Revenue
58.82 M
R&D Expenses
11.68 M
Operating CF
2.73 M
Total Assets
504.61 M
Total Liabilities
104.71 M
Equity
399.90 M
D/E Ratio
12,345
-9.12 %
Week
-10.6 %
1 Month
-20.67 %
3 Month
-33.69 %
6 Month
-21.81 %
5 Year
-95.55 %
All Time
Cash Data
Cash Position
146.68 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 5, 2026
Overview
Volume
462.53 K
52 Week Range
18.14 - 52.24
% held by Insiders
3.32 %
% held by Institutions
93.23 %
Enterprise Value
435.78 M
Total Shares
18.50 M
Short %
19.65 %
Float Shares
16.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rigel Pharmaceuticals, Inc.
910Total events
5Upcoming
211Tier-1 (high impact)
2009 – 2028Coverage
Upcoming catalysts 5
Event history 905
Jul 1, 2026
Jun 13, 2026
◆Poster PresentationREZLIDHIAPresentation
Real-world treatment patterns and outcomes with olutasidenib after venetoclax in IDH1-mutated AML using EHR data presented as poster at EHA 2026
relapsed or refractory mIDH1 acute myeloid leukemiasource ↗
Jun 11, 2026
▲Partnership / LicenseVEPPANUCorporate
Closing of exclusive global license agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant)
ER+/HER2- ESR1-mutated advanced or metastatic breast cancersource ↗
Jun 3, 2026
Jun 1, 2026
◆Poster PresentationREZLIDHIAPresentation
Long-term response characteristics to olutasidenib in AML presented as poster at ASCO 2026
relapsed or refractory mIDH1 acute myeloid leukemiasource ↗
May 30, 2026
◆Poster PresentationGAVRETOPresentation
Final analysis of pralsetinib in advanced or metastatic RET-altered thyroid cancer from ARROW study presented as poster at ASCO 2026
RET-altered thyroid cancersource ↗
May 29, 2026
◆Oral PresentationGAVRETOPresentation
Final data from Phase 3 AcceleRET-Lung trial of pralsetinib as first-line treatment of RET fusion-positive NSCLC presented in oral session at ASCO 2026
RET fusion-positive non-small cell lung cancersource ↗
May 19, 2026
◆Oral PresentationPresentation
Rigel presents company overview at 2026 RBC Capital Markets Global Healthcare Conference
May 12, 2026
▲Partnership / LicenseVEPPANUCorporate
Rigel enters exclusive global license agreement for VEPPANU from Arvinas and Pfizer
ER+/HER2-, ESR1m mBCsource ↗
May 12, 2026
▲Milestone PaymentVEPPANUCorporate
Upfront payment of $70M and potential $15M transition milestone
Drug Pipeline Intelligence
C56
Pipeline Score $1.1B
Pipeline ValueFair Value
Valuation Signal11
Drugs Scored2.1x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 911)
Percentile RankRigel Pharmaceuticals, Inc. carries a moderate pipeline score (56/100), with $2.8B risk-adjusted pipeline value, led by Ruxolitinib in Coronavirus (Phase 1), across $194B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ruxolitinib Small molecule | Coronavirus | Phase 1 | NCT04581954 | 12% | $659M | COMPLETED | 185 | - | - | Sep 2, 2023 | - | Nov 18, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
vepdegestrant | 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer | Phase 3 | 2026-05-12 | mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement Read More | Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Read More | |
vepdegestrant | 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer | Phase 3 | 2026-05-12 | mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement Read More | Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Read More | |
vepdegestrant | 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer | Phase 3 | 2026-05-12 | mPFS of 5.0 months vs. 2.1 months for fulvestrant, a 2.4-fold improvement Read More | Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RIGL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RIGL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RIGLRigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer
Rigel Pharmaceuticals has appointed Dr. Alison L. Hannah as Chief Medical Officer, effective July 1, 2026. Dr. Hannah, who has served on Rigel's Board since 2021, resigns from her board position to take on this executive role. She brings significant experience in oncology and will lead the development of Rigel's pipeline, including investigational therapies for hematologic disorders and cancer.
Read more →RIGLRigel Announces Closing of Licensing Agreement for VEPPANU™ (vepdegestrant)
Rigel Pharmaceuticals has finalized a licensing agreement for VEPPANU (vepdegestrant), an FDA-approved treatment for advanced breast cancer. The agreement, effective June 11, 2026, includes a $70 million upfront payment to Arvinas and Pfizer. Rigel plans to make VEPPANU commercially available by August 2026, despite potential risks associated with its use.
Read more →RIGLRigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. will present an overview at the Jefferies Global Healthcare Conference on June 3, 2026. CEO Raul Rodriguez will lead the presentation, showcasing the company's focus on hematologic disorders and cancer. Interested parties can access the live webcast through Rigel's website.
Read more →RIGLRigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress
Rigel Pharmaceuticals announced that it will present final data from the Phase 3 AcceleRET-Lung trial for GAVRETO at the 2026 ASCO Annual Meeting. Additionally, the company will showcase further data on pralsetinib and REZLIDHIA at both the ASCO and EHA 2026 Congress. These presentations emphasize Rigel's commitment to enhancing treatment options for patients with hematologic disorders and cancer.
Read more →RIGLRigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference
Rigel Pharmaceuticals announced that CFO Dean Schorno will present at the 2026 RBC Capital Markets Global Healthcare Conference. The presentation is scheduled for May 19 at 9:30 a.m. ET in New York. This event reflects Rigel's commitment to engaging with the investment community and discussing its advancements in hematologic disorders and cancer treatments.
Read more →RIGL▲ +12.1%on this news· ran to +23% by day 1shared move
Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Rigel Pharmaceuticals has entered an exclusive global licensing agreement with Arvinas and Pfizer to develop and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC, targeting advanced or metastatic breast cancer. The drug showed a significant 2.4-fold improvement in progression-free survival compared to the standard treatment, fulvestrant, during the Phase 3 VERITAC-2 trial. Rigel expects VEPPANU to substantially contribute to revenue growth and fill an important gap in treatment for patients with ESR1 mutations who have limited options following endocrine therapy. The agreement is set to close in mid-June 2026, pending regulatory clearance.
Read more →RIGL▼ -5.1%on this news
Rigel Reports First Quarter 2026 Financial Results
Rigel Pharmaceuticals reported strong financial results for Q1 2026, with total revenues of $58.8 million, a 26% increase from the previous year. The company achieved profitability with a net income of $8.7 million, although this was lower than the prior year's figure. Rigel continues to advance its clinical development pipeline, particularly the R289 study for lower-risk MDS, while maintaining a solid cash position.
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results
Rigel Pharmaceuticals will announce its first quarter 2026 financial results on May 5, 2026, after market close. Following the announcement, senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with a replay available for 90 days.
Read more →RIGL▲ +5%on this news
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced inducement grants under NASDAQ Listing Rule 5635(c)(4) to support employee recruitment. The company awarded 8,925 restricted stock units to six non-executive employees, with a vesting schedule of four years. This initiative is part of Rigel's strategy to attract talent and enhance employee retention. Rigel, focused on developing therapies for hematologic disorders and cancer, continues to emphasize its commitment to its workforce.
Read more →RIGL▲ +5.1%on this news
Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
Rigel Pharmaceuticals announced the publication of final data from the Phase 1/2 ARROW study on pralsetinib for treating RET fusion-positive NSCLC. The results indicate a 70% overall response rate and emphasize the drug's manageable safety profile. The findings support pralsetinib's potential as a first-line treatment option, particularly for patients with measurable CNS metastases.
Read more →RIGL▼ -10.3%on this news
Rigel Provides Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Rigel Pharmaceuticals reported strong financial results for Q4 and full year 2025, with record net product sales and a significant increase in net income. The company highlighted its progress in clinical development, particularly with the R289 program for lower-risk MDS. Rigel anticipates continued growth and positive net income for 2026, despite rising costs associated with R&D efforts.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update
Rigel Pharmaceuticals will announce its fourth quarter and full year 2025 financial results on March 3, 2026. Following the announcement, a live conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. The call will be accessible via phone and webcast, with an archived version available for 90 days.
Read more →RIGLRigel Appoints Michael P. Miller to the Board of Directors
Rigel Pharmaceuticals has appointed Michael P. Miller to its Board of Directors. With over 40 years in the biotech and pharmaceutical sectors, Miller's experience is expected to enhance Rigel's strategic initiatives. He has previously held significant roles at Jazz Pharmaceuticals and Genentech, among others, and is eager to contribute to Rigel's mission in hematologic disorders and cancer.
Read more →RIGLRigel Provides Business Update and 2026 Outlook Preliminary fourth quarter 2025 total revenue of approximately $69.8 million, including net product sales of $65.4 million and contract revenues of $4.4 million In the dose
Rigel Pharmaceuticals reported a strong business update with preliminary total revenue of approximately $69.8 million for the fourth quarter of 2025, an increase from $57.6 million in 2024. The ongoing Phase 1b study of R289 for lower-risk MDS is showing promising results, with a 33% rate of achieving red blood cell transfusion independence in certain patient groups. Looking ahead, Rigel forecasts total revenues of approximately $275 to $290 million for 2026, including product sales and a positive net income. However, final results for the quarter are still pending an audit, which introduces a level of uncertainty.
Read more →RIGL▲ +8.7%on this newsshared move
Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Raul Rodriguez will provide a company overview during the event. The conference is a significant platform for showcasing Rigel's advancements in therapies for hematologic disorders and cancer.
Read more →RIGL▼ -11.3%on this news
Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition
Rigel Pharmaceuticals presented updated data from its ongoing Phase 1b study of R289 at the 67th ASH Annual Meeting. The study focuses on patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). The results indicate promising efficacy and safety, with plans to finalize the recommended Phase 2 dose by mid-2026.
Read more →RIGLRigel to Present at the Piper Sandler 37th Annual Healthcare Conference
Rigel Pharmaceuticals, Inc. will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025. Dean Schorno, the CFO, will provide a company overview during the event. Investors can access the live webcast through the company's website, ensuring they connect beforehand for any necessary software downloads.
Read more →RIGLRigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology
Rigel Pharmaceuticals announced the publication of final five-year data on REZLIDHIA (olutasidenib) for treating relapsed or refractory mIDH1 acute myeloid leukemia (AML). The data, published in the Journal of Hematology & Oncology, confirms the drug's durable responses and manageable safety profile, including in patients previously treated with venetoclax. The findings further enhance the potential impact of olutasidenib on patient outcomes.
Read more →RIGL▲ +5.2%on this newsshared move
Rigel to Present at the Jefferies Global Healthcare Conference in London
Rigel Pharmaceuticals will present at the Jefferies Global Healthcare Conference in London on November 18, 2025. CEO Raul Rodriguez will provide an overview of the company during the event. Investors can access the live webcast through Rigel's website. The company focuses on therapies for hematologic disorders and cancer.
Read more →RIGL▲ +33.4%on this news
Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update
Rigel Pharmaceuticals reported strong financial results for Q3 2025, with total revenues of $69.5 million, a 65% increase from the previous year. The company raised its full-year revenue guidance to approximately $285 to $290 million, citing robust commercial performance. Additionally, Rigel's development pipeline is progressing, particularly with the R289 study for lower-risk MDS. The company also reported a net income of $27.9 million for the quarter.
Read more →RIGLRigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition
Rigel Pharmaceuticals announced that it will present data from its Phase 1b study of R2891 at the 67th American Society of Hematology Annual Meeting. The study focuses on patients with relapsed or refractory lower-risk myelodysplastic syndrome. Additionally, four poster presentations will showcase data on REZLIDHIA for treating acute myeloid leukemia. The meeting will take place from December 6-9, 2025, in Orlando, Florida.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals will announce its third quarter 2025 financial results on November 4, 2025. Following the announcement, a live conference call and webcast will be held at 4:30 p.m. ET to discuss the results and provide a business update. Participants can join via phone or through the company's website.
Read more →RIGLRigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS
Rigel Pharmaceuticals has announced the enrollment of the first patient in the dose expansion phase of its Phase 1b study for R289, targeting patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS). This phase will help determine the recommended Phase 2 dose of R289. The study aims to address a significant unmet need in this patient population, with results expected later this year.
Read more →RIGLRigel to Participate in Upcoming September Investor Conferences
Rigel Pharmaceuticals announced participation in investor conferences in September. CEO Raul Rodriguez and CFO Dean Schorno will present at these events, highlighting the company's focus on hematologic disorders and cancer. Interested parties can access live webcasts and recordings through Rigel's Investor Relations section. This engagement reflects Rigel's commitment to investor communication.
Read more →RIGL▲ +6.9%on this news· ran to +40% by day 3
Rigel Reports Second Quarter 2025 Financial Results and Provides Business Update Second quarter 2025 total revenue of approximately $101.7 million, which includes net product sales of $58.9 million and contract revenues
Rigel Pharmaceuticals reported strong financial results for the second quarter of 2025, with total revenues of approximately $101.7 million and net product sales growing by 76% year-over-year. The company completed the enrollment for a Phase 1b study of R289, an IRAK1/4 inhibitor, and has raised its financial guidance for the year, now anticipating total revenue between $270 million and $280 million. However, increased operational expenses related to product sales and R&D could impact future profits. The conference call scheduled today will provide further insights into the company’s performance and outlook.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. announced that it will report its second quarter 2025 financial results on August 5, 2025. The announcement includes a live conference call and webcast scheduled for the same day, allowing participants to engage directly with senior management. The company is committed to informing stakeholders about its financial performance and current business updates. The webcast will also be archived for later access.
Read more →RIGL▼ -5.8%on this newsshared move
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress
Rigel Pharmaceuticals announced seven upcoming poster presentations at the 2025 ASCO Annual Meeting and EHA 2025 Congress. The presentations will feature significant data on GAVRETO (pralsetinib) for RET fusion-positive NSCLC and REZLIDHIA (olutasidenib) for relapsed or refractory mIDH1 AML. Notably, the ARROW study reported a 70.3% overall response rate for GAVRETO in NSCLC patients. Additionally, evidence presented for REZLIDHIA indicates its potential benefits in earlier treatment lines for challenging R/R AML cases.
Read more →RIGLRigel Reports First Quarter 2025 Financial Results and Provides Business Update First quarter 2025 total revenue of approximately $53.3 million, which includes net product sales of $43.6 million and contract revenues fro
Rigel Pharmaceuticals reported robust Q1 2025 results, with total revenue of approximately $53.3 million, driven primarily by net product sales. The company achieved a net income of $11.4 million, a significant improvement from a loss in the same quarter of the previous year. The FDA granted R289 Orphan Drug and Fast Track designations for the treatment of myelodysplastic syndromes, bolstering its pipeline. Rigel forecasts total revenues for 2025 to reach between $200 and $210 million.
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. has announced it will report its first quarter 2025 financial results on May 6, 2025. Following the announcement, there will be a live conference call and webcast led by the company's senior management to discuss the results and provide a business update. The conference call will be accessible to investors and interested parties via phone and will also be streamed online, with an option to replay for 90 days.
Read more →RIGLRigel Announces Settlement Agreement Resolving TAVALISSE (fostamatinib disodium hexahydrate) Patent Litigation
Rigel Pharmaceuticals has announced a settlement agreement with Annora Pharma that resolves patent litigation over TAVALISSE, its treatment for chronic immune thrombocytopenia (ITP). Under the agreement, Annora will be permitted to sell a generic version of TAVALISSE by the second quarter of 2032, subject to certain conditions. This settlement not only reinforces Rigel's intellectual property rights but also allows the company to focus on advancing its portfolio of therapies designed to improve the lives of patients with blood disorders. The litigation has now been terminated, which is expected to result in reduced legal burdens for Rigel.
Read more →RIGLRigel Appoints Mark W. Frohlich, M.D. to Board of Directors
Rigel Pharmaceuticals has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich, a seasoned medical oncologist with extensive experience in developing cellular immunotherapies, will assist in advancing Rigel's hematology and oncology development pipeline. He previously held significant roles in various biotechnology firms, including Juno Therapeutics and Dendreon Corporation. His appointment is seen as a strategic move to leverage his expertise in enhancing Rigel's therapeutic offerings.
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE net product sales of $31.0 million
Rigel Pharmaceuticals reported its financial results for Q4 and full year 2024, revealing total revenues of approximately $57.6 million in the fourth quarter. The company saw significant growth in net product sales, particularly with TAVALISSE and REZLIDHIA, leading to a net income of $14.3 million for Q4. With total revenues for the full year at $179.3 million, Rigel anticipates generating approximately $200 to $210 million in total revenue for 2025 while continuing to fund clinical development programs.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. has announced that it will report its financial results for the fourth quarter and full year of 2024 on March 4, 2025. Following this announcement, Rigel senior management will host a live conference call and webcast to discuss the results and provide a business update. Participants will have the option to join via phone or through a live webcast, which will also be available for replay. Rigel continues its dedication to developing therapies for hematologic disorders and cancer.
Read more →RIGLRigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and...
Rigel Pharmaceuticals announced the enrollment of the first patient in a Phase 1 study evaluating fostamatinib, an oral SYK inhibitor, for treating sickle cell disease. Sponsored by the NHLBI, the study aims to assess the safety and tolerability of the drug, which may potentially alleviate complications associated with the disease. Fostamatinib, already approved for chronic immune thrombocytopenia, is being investigated due to promising preclinical results indicating its benefits for sickle cell patients. The trial is expected to enroll approximately 20 patients over its course.
Read more →RIGL▲ +5.3%on this news
Rigel Provides Business Update and 2025 Outlook
Rigel Pharmaceuticals provided a business update detailing preliminary revenue figures for Q4 2024, estimating approximately $57.6 million. The company announced successful product sales, with TAVALISSE and REZLIDHIA achieving record numbers and the addition of GAVRETO contributing to their portfolio. Rigel also received Orphan Drug designation for its treatment R289 and anticipates continued growth with a projected revenue of $200 to $210 million in 2025. Financial stability was highlighted as the company reached breakeven in 2024.
Read more →RIGL▲ +5.3%on this news
Rigel Provides Business Update and 2025 Outlook Preliminary fourth quarter 2024 total revenue of approximately $57.6 million which includes TAVALISSE net product sales of $31.0 million, REZLIDHIA net product sales of $7.
Rigel Pharmaceuticals, Inc. provided a business update highlighting preliminary total revenues for Q4 2024 of approximately $57.6 million, which includes notable net product sales. The company announced record sales for TAVALISSE and REZLIDHIA and is optimistic about its pipeline developments, including a promising study of R289 in lower-risk MDS. Rigel expects to achieve positive net income in 2025 while maintaining financial discipline and advancing its product offering. Full financial results for the year ended December 31, 2024, are expected to be announced in March 2025.
Read more →RIGLRigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel Pharmaceuticals announced that the FDA has granted Orphan Drug designation to R289, aimed at treating myelodysplastic syndromes (MDS). This designation underscores a significant unmet medical need for patients with MDS and provides incentives for its development. R289, which is under investigation in a Phase 1b trial, is a dual inhibitor targeting IRAK1 and IRAK4. Alongside its Fast Track designation, Rigel aims to advance R289 as a potential therapeutic option for patients with lower-risk MDS.
Read more →RIGLRigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that its CEO, Raul Rodriguez, will present an overview of the company at the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. This presentation is scheduled for January 16, 2025, and aims to outline Rigel's efforts in developing therapies for hematologic disorders and cancer. Interested parties can access the live webcast through the company's website, which emphasizes Rigel's ongoing engagement with investors and stakeholders.
Read more →RIGL▼ -9%on this news· ran to -25% by day 3
Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66 th ASH Annual Meeting and Exposition R289 was generally well tolerated and demonstrated signs of preliminary clinical activity
Rigel Pharmaceuticals presented initial data from its ongoing Phase 1b study of R289 for lower-risk myelodysplastic syndrome at the 66th ASH Annual Meeting. The study indicates R289 is generally well tolerated, exhibiting signs of preliminary clinical activity, particularly in achieving transfusion independence in 40% of evaluable patients. The results are promising enough to garner Fast Track designation from the FDA, suggesting potential for R289 as a new treatment option. However, some patients experienced significant adverse events, highlighting the study's challenges.
Read more →RIGLRigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDS
Rigel Pharmaceuticals has announced that the FDA has granted Fast Track designation to its investigational drug R289 for the treatment of previously-treated transfusion-dependent lower-risk myelodysplastic syndrome (LR-MDS). This designation aims to expedite the development and review process for drugs treating serious conditions with an unmet medical need. R289 is currently undergoing a Phase 1b study focused on its safety and preliminary efficacy. The company's leadership has expressed confidence in R289's potential to improve the lives of patients suffering from this condition.
Read more →RIGL▲ +9.1%on this news
Rigel to Present at the Jefferies London Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that its CFO, Dean Schorno, will present an overview at the Jefferies London Healthcare Conference on November 19, 2024. This event showcases Rigel's commitment to engaging with stakeholders and providing insights into its business strategy and pipeline. Investors can access the live webcast through the company's website, emphasizing transparency in communications. Rigel continues to focus on developing novel therapies for hematologic disorders and cancer.
Read more →RIGLRigel Reports Third Quarter 2024 Financial Results and Provides Business Update Third quarter total revenue of $55.3 million, which includes TAVALISSE net product sales of $26.3 million, REZLIDHIA net product sales of $5
Rigel Pharmaceuticals (RIGL) reported its third quarter 2024 financial results, revealing total revenues of $55.3 million. The report highlighted significant net product sales from TAVALISSE, REZLIDHIA, and GAVRETO. Rigel's net income showed a turnaround to $12.4 million, compared to a loss in the same quarter last year. The company also announced an agreement with Kissei for the development of REZLIDHIA in Asia and presented positive initial data from ongoing clinical studies.
Read more →RIGLRigel Announces Six Poster Presentations at the 66th American Society of Hematology Annual Meeting and Exposition
Rigel Pharmaceuticals announced six poster presentations at the upcoming 66th American Society of Hematology Annual Meeting, showcasing data from their hematology-oncology portfolio. Notably, preliminary results from a Phase 1b study of R289 in lower-risk myelodysplastic syndrome (LR-MDS) indicate favorable safety and efficacy outcomes. Additionally, the company will present findings on REZLIDHIA® (olutasidenib) in patients with mutated isocitrate dehydrogenase-1 acute myeloid leukemia (mIDH1 AML), which emphasize its clinical benefits in challenging patient populations. The meeting, taking place from December 7-10, 2024, in San Diego, will address unmet medical needs in blood disorders and cancer treatment.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. has announced it will release its financial results for the third quarter of 2024 after market close on November 7, 2024. Following the announcement, the company will host a live conference call and webcast to discuss the results and provide a business update. Participants can access the call via dial-in or through the company's website, where the replay will be available for 90 days. Rigel focuses on developing therapies for cancer and hematologic disorders.
Read more →RIGLRigel Pharmaceuticals Issues Dear Healthcare Provider Letter for GAVRETO® (pralsetinib)
Rigel Pharmaceuticals has issued a Dear Healthcare Provider letter regarding a new safety signal for GAVRETO (pralsetinib) after consultations with the FDA. This communication aims to inform healthcare providers about potential risks associated with the drug, highlighting severe adverse reactions such as interstitial lung disease and hypertension. Rigel continues to prioritize patient safety and encourages the reporting of any adverse events. Detailed safety information and instructions for monitoring patients are also included in the communication.
Read more →RIGLRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. announced the granting of 35,944 stock options to fifteen non-executive employees as part of its Inducement Plan. This initiative, approved by Rigel's Board of Directors, is designed to incentivize new hires in accordance with NASDAQ Listing Rule 5635(c)(4). The stock options will vest over a period of four years, with a one-year cliff. Rigel is focused on developing novel therapies for patients with hematologic disorders and cancer.
Read more →RIGLRigel to Present at the 2024 Cantor Global Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that its president and CEO, Raul Rodriguez, will present a company overview at the 2024 Cantor Global Healthcare Conference. The presentation is scheduled for September 19 at 9:10 am ET in New York, NY. Individuals interested in the presentation can access it via Rigel's Investor Relations website. This engagement highlights Rigel's ongoing commitment to raising awareness about its focus on hematologic disorders and cancer therapies.
Read more →RIGLRigel Announces First Patient Enrolled in Phase 1b/2 Triplet Therapy Trial of REZLIDHIA® (olutasidenib) in mIDH1 AML
Rigel Pharmaceuticals has announced the enrollment of the first patient in a Phase 1b/2 clinical trial for its drug REZLIDHIA (olutasidenib) in combination with decitabine and venetoclax for treating mIDH1 acute myeloid leukemia (AML). This marks the beginning of Rigel's strategic partnership with the University of Texas MD Anderson Cancer Center. The trial aims to evaluate the safety and efficacy of this triplet therapy in patients suffering from mutated idh1 AML. The collaboration with MD Anderson is expected to explore the potential of REZLIDHIA in various hematologic conditions.
Read more →RIGLRigel Expands Relationship with Kissei to include REZLIDHIA® (olutasidenib) in Japan, the Republic of Korea and Taiwan
Rigel Pharmaceuticals has expanded its partnership with Kissei Pharmaceutical to include the commercialization of REZLIDHIA (olutasidenib) across Japan, the Republic of Korea, and Taiwan. The deal entails an upfront payment of $10 million, with further milestone payments potentially reaching $152.5 million based on development and commercial progress. Kissei will lead the clinical studies and seek regulatory approval for REZLIDHIA in Japan, targeting relapsed or refractory acute myeloid leukemia. This strategic move is expected to enhance patient access to treatment in these regions.
Read more →RIGL▲ +6%on this news· ran to +16% by day 3
Rigel Reports Second Quarter 2024 Financial Results and Provides Business Update Second quarter total revenue of $36.8 million, which includes TAVALISSE net product sales of $26.4 million, REZLIDHIA net product sales of
Rigel Pharmaceuticals reported its financial results for the second quarter of 2024, showing total revenues of $36.8 million, boosted by significant sales of TAVALISSE and REZLIDHIA. Notably, REZLIDHIA experienced a 102% increase in net sales compared to the previous year. Despite these revenue gains, the company reported a net loss of $1.0 million and faced rising expenses associated with product sales and research. The integration of GAVRETO into their portfolio signifies a strategic advancement in their commercial operations.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. announced that it will release its second quarter financial results on August 6, 2024. Following the results, the company will host a live conference call and webcast at 4:30 p.m. ET to discuss the outcomes and provide a business update. Participants can join the call either via telephone or through the company's website, where the session will also be archived for later viewing.
Read more →RIGL▲ +20.6%on this news
Rigel Announces Reverse Stock Split SOUTH SAN FRANCISCO, Calif. , June 25 , 2024 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will effect a reverse stock split of its issued and outs
Rigel Pharmaceuticals announced a 1-for-10 reverse stock split effective on June 27, 2024. This decision, approved by stockholders, aims to increase the per-share trading price of Rigel's stock and improve its marketability to investors. Approximately 175 million shares will be reduced to about 17.5 million shares post-split. The company hopes this action will help maintain compliance with Nasdaq's minimum bid price requirement.
Read more →RIGL▼ -11.9%on this newsshared move
Rigel Announces Reverse Stock Split
Rigel Pharmaceuticals, Inc. has announced a reverse stock split of its common stock at a ratio of 1-for-10, effective June 27, 2024. This decision aims to raise the per-share trading price and improve marketability to institutional investors, addressing concerns regarding the company's current low stock price. The reverse split was approved by stockholders and will reduce approximately 175 million shares to about 17.5 million shares, with proportional adjustments to equity plans. Rigel's common stock will continue trading under the same symbol, RIGL, post-split.
Read more →RIGLRigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Rigel Pharmaceuticals has announced the completion of the transfer of the New Drug Application (NDA) for GAVRETO (pralsetinib), which targets RET fusion-positive non-small cell lung cancer and thyroid cancer. The drug will be available in the U.S. starting June 27, 2024, allowing for greater patient access. It is highlighted as a once-daily oral therapy, with specific FDA approvals for its indications, although the approval for thyroid cancer is under accelerated terms pending further trial results. Rigel's strategic acquisition of GAVRETO enhances its oncology portfolio significantly.
Read more →RIGLRigel Announces Five Presentations at the EHA2024 Hybrid Congress
Rigel Pharmaceuticals announced five presentations at the EHA 2024 Hybrid Congress, focusing on olutasidenib (REZLIDHIA) for relapsed or refractory mIDH1 acute myeloid leukemia (AML). The oral presentation highlighted final five-year efficacy data from a Phase 2 trial, indicating significant outcomes for heavily pretreated patients. New data also demonstrated olutasidenib's effects in patients with mIDH1 AML secondary to myeloproliferative neoplasms and the potential use of the therapy as a bridge to transplant. Overall, the findings support olutasidenib's effectiveness and manageable safety profile across multiple patient subgroups.
Read more →RIGLRigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
Rigel Pharmaceuticals announced key findings from three poster presentations at the 2024 ASCO Annual Meeting. Highlights included long-term results from the Phase 2 trial of REZLIDHIA in patients with relapsed or refractory mIDH1 AML, showcasing durable responses and favorable safety in elderly patients. The company also shared preliminary insights on the Phase 1b trial of R289, a new candidate for treating lower-risk myelodysplastic syndrome. Despite the positive data, potential risks such as differentiation syndrome and hepatotoxicity were noted.
Read more →RIGLRigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress
Rigel Pharmaceuticals has announced that it will present new data on its oncology and hematology portfolio at the upcoming 2024 ASCO and EHA conferences. This includes final five-year results indicating the strong efficacy of REZLIDHIA (olutasidenib) in relapsed/refractory mIDH1 AML patients, especially those who are elderly or have previously been treated with venetoclax. The data highlight both the safety profile of REZLIDHIA and its potential as a treatment that can lead to remission, providing hope for patients in challenging circumstances.
Read more →RIGLRigel Reports First Quarter 2024 Financial Results and Provides Business Update First quarter 2024 total revenue of $29.5 million, which includes TAVALISSE net product sales of $21.1 million and REZLIDHIA net product sal
Rigel Pharmaceuticals, Inc. reported its Q1 2024 financial results, showing total revenues of $29.5 million, with significant sales from TAVALISSE and REZLIDHIA. Despite strong demand that led to record bottle sales for both drugs, TAVALISSE's net sales declined compared to the previous year. The company also reported a net loss, although it was an improvement over the same quarter in 2023. Rigel is moving forward with its product pipeline and plans to introduce GAVRETO later this year.
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. announced that it will report its first quarter 2024 financial results after the market close on May 7, 2024. A live conference call and webcast will follow the announcement to discuss these results and provide a business update. Participants can join the call via a dedicated number, and the session will also be available for replay for 90 days on Rigel's website. This announcement emphasizes Rigel's commitment to transparency and engagement with stakeholders.
Read more →RIGLRigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals announced a publication on the efficacy of REZLIDHIA (olutasidenib) in patients with mutant IDH1 acute myeloid leukemia who were relapsed or refractory to venetoclax treatments. In the study, 43.8% of patients achieved durable composite complete remissions, indicating the potential of olutasidenib as a new treatment option for this difficult patient population. The safety profile was consistent with previous studies, but there were concerns about differentiation syndrome and hepatotoxicity in treated patients. These findings may offer hope for patients facing limited options after standard therapies fail.
Read more →RIGLRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer
Rigel Pharmaceuticals announced the appointment of Dr. Lisa Rojkjaer as Chief Medical Officer, highlighting her extensive experience in clinical development and hematology. The company expressed confidence that her expertise will help advance its clinical portfolio, particularly in hematology and oncology. Rigel has ongoing collaborations aimed at evaluating treatments for IDH1-mutant cancers and lower-risk myeloid dysplastic syndrome. However, the announcement also included caution regarding forward-looking statements and inherent risks in clinical development and regulatory pathways.
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Fourth quarter 2023 Total Revenue of $35.8 million which includes TAVALISSE net product sales of $25.7 million and REZLIDHIA
Rigel Pharmaceuticals reported its financial results for the fourth quarter and full year 2023, highlighting total revenue of $35.8 million in Q4, bolstered by TAVALISSE and REZLIDHIA sales. The company achieved a 36% increase in overall sales for 2023 compared to the previous year, reaching $104.3 million. However, Rigel also recorded a net income drop in Q4 2023 and a net loss of $25.1 million for the full year, despite reduced costs in other areas. The company is focusing on commercial expansion and pipeline advancement through strategic collaborations.
Read more →RIGL▲ +5.6%on this news
Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update
Rigel Pharmaceuticals announced that it will report its fourth quarter and full year 2023 financial results on March 5, 2024. Following the report, a conference call and webcast will take place to discuss the results and provide a business update. Interested participants can join the call via phone or online, with the webcast available for replay for 90 days after the event.
Read more →RIGL▲ +16.1%on this news· ran to +34% by day 3shared move
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Rigel Pharmaceuticals has obtained the U.S. rights to GAVRETO (pralsetinib) from Blueprint Medicines for $15 million, aimed at expanding its oncology portfolio. GAVRETO is a targeted therapy approved for RET fusion-positive metastatic non-small cell lung cancer and advanced thyroid cancer, generating approximately $28 million in net product sales in 2023. The transaction allows Rigel to leverage its existing infrastructure, enhancing access to this critical treatment. Following the acquisition, additional milestone payments may be due based on future sales, while ongoing FDA discussions may affect the future of GAVRETO's approvals.
Read more →RIGL▲ +7.2%on this news
Rigel Pharmaceuticals Provides Business Update Preliminary fourth quarter 2023 total revenue of approximately $35.7 million which includes record TAVALISSE net product sales of $25.7 million and REZLIDHIA net product sal
Rigel Pharmaceuticals announced a strong preliminary total revenue of approximately $35.7 million for the fourth quarter of 2023, driven by record net product sales of TAVALISSE and significant growth from REZLIDHIA. CEO Raul Rodriguez highlighted a 24% increase in TAVALISSE sales over the previous year. The company plans to focus on commercial execution, advancing its hematology-oncology pipeline, and achieving financial breakeven in the upcoming period. Complete financial results for Q4 and the full year will be disclosed in March 2024.
Read more →RIGL▲ +7.2%on this news
Rigel Pharmaceuticals Provides Business Update
Rigel Pharmaceuticals announced a business update revealing preliminary total revenue of about $35.7 million for the fourth quarter of 2023. This includes TAVALISSE net sales of $25.7 million, a nearly 24% increase from the previous year, and REZLIDHIA sales of $3.9 million, significantly higher than last year. The company has established collaborations with MD Anderson to explore REZLIDHIA's application in various cancers and with CONNECT for a Phase 2 trial in glioma. Overall, Rigel reported $104 million in total product sales for 2023, marking a 36% growth over the previous year.
Read more →RIGLRigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma
Rigel Pharmaceuticals announced a collaboration with CONNECT to conduct a Phase 2 clinical trial evaluating olutasidenib in pediatric patients with high-grade glioma harboring an IDH1 mutation. The trial will assess the drug's efficacy when combined with temozolomide as maintenance therapy. Rigel plans to fund the study up to $3 million over four years. The primary goal of the trial is to estimate progression-free survival while also characterizing safety and pharmacokinetics. The study is slated to begin enrolling patients in the first half of 2024.
Read more →RIGLRigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that its president and CEO, Raul Rodriguez, will deliver a company overview at the 42nd Annual J.P. Morgan Healthcare Conference. This event is scheduled for January 11, 2024, in San Francisco, CA. The conference presents a platform for Rigel to showcase its advancements in therapies for hematologic disorders and cancer, aligning with its mission to improve patient outcomes. Interested parties can access the presentation through the company's Investor Relations website.
Read more →RIGL▲ +16.2%on this news
Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers
Rigel Pharmaceuticals and MD Anderson Cancer Center have announced a strategic alliance to enhance the development of REZLIDHIA (olutasidenib) for treating acute myeloid leukemia (AML) and other cancers. This collaboration aims to evaluate the drug's efficacy as a monotherapy and in combination therapies, targeting newly diagnosed and R/R patients. Rigel will contribute $15 million in funding over the five-year partnership, while retaining program rights. The potential benefits of olutasidenib are notable, although safety concerns such as differentiation syndrome and hepatotoxicity are highlighted in the announcement.
Read more →RIGLRigel Reports Third Quarter 2023 Financial Results and Provides Business Update Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE net product sales of $24.5 million and REZLIDHIA net produ
Rigel Pharmaceuticals reported its financial results for the third quarter of 2023, showcasing total revenues of $28.1 million driven by strong sales of TAVALISSE and REZLIDHIA. TAVALISSE reached record net product sales of $24.5 million, marking a 27% increase from the prior year. Despite a net loss of $5.7 million, the company noted progress towards financial breakeven thanks to improved expense management. Overall, the financial performance reflects Rigel's strong momentum in its hematology-oncology portfolio.
Read more →RIGLRigel Announces Poster Presentations at the 65th American Society of Hematology Annual Meeting and Exposition
Rigel Pharmaceuticals announced the presentation of four posters at the upcoming 65th American Society of Hematology Annual Meeting. These presentations will focus on the data surrounding olutasidenib for treating relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. Preliminary results indicate promising efficacy, yet highlight safety concerns with treatment-emergent adverse events affecting all trial participants. The company is optimistic about the potential improvements in patient outcomes as they expand their hematology-oncology portfolio.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2023 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. will report its third quarter 2023 financial results after market close on November 7, 2023. Following the announcement, Rigel's senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial outcomes and provide a business update. The call will be accessible to investors and media, ensuring transparency regarding the company's performance and strategic direction.
Read more →RIGLRigel Announces Presentation at the Upcoming IDWeek 2023
Rigel Pharmaceuticals announced a presentation of data from its FOCUS Phase 3 trial on fostamatinib, targeting COVID-19 patients requiring oxygen, at IDWeek 2023. The trial met its primary endpoint, showing a reduction in days on oxygen for patients receiving fostamatinib compared to placebo. However, enrollment for the ACTIV-4 Host Tissue trial has been recommended to cease due to low expected benefits for patients. Rigel's ongoing focus remains on their hematology-oncology portfolio in light of these findings and regulatory feedback.
Read more →RIGLRigel to Present at the 2023 Cantor Global Healthcare Conference
Rigel Pharmaceuticals, Inc. has announced that its chief financial officer, Dean Schorno, will present a company overview at the Cantor Global Healthcare Conference on September 27, 2023. This event will be held in New York City and will provide investors with insights into Rigel's operations and strategies. The conference presentation is part of Rigel's efforts to enhance its communication with investors and share developments regarding its therapies for hematologic disorders and cancer.
Read more →RIGLRigel Reports Second Quarter 2023 Financial Results and Provides Business Update Second quarter 2023 Total Revenue of $26.9 million which includes TAVALISSE net product sales of $21.3 million and REZLIDHIA net product sa
Rigel Pharmaceuticals reported its Q2 2023 financial results, highlighting total revenue of $26.9 million driven mainly by TAVALISSE and REZLIDHIA sales. The company achieved significant revenue growth for TAVALISSE and completed enrollment for a Phase 1b trial of R289, while also showing promising clinical data for REZLIDHIA in AML patients. Despite this progress, Rigel recorded a net loss of $6.6 million, although this is reduced compared to the previous year. Overall, Rigel is advancing its product offerings while managing its operational costs.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2023 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. has announced that it will report its second quarter 2023 financial results after market close on August 1, 2023. Following this announcement, the company's senior management will host a live conference call and webcast at 4:30 p.m. Eastern Time. The call aims to discuss the financial results and provide an update on the business operations and pipeline. The webcast will also be available for replay for 90 days following the event.
Read more →RIGLRigel Announces Presentation of Data from Analysis of REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML
Rigel Pharmaceuticals announced promising data at the EHA 2023 Congress regarding its drug REZLIDHIA (olutasidenib) for patients with mutant IDH1 acute myeloid leukemia (AML) who are relapsed or refractory to venetoclax. The Phase 2 study showed durable remissions in patients, with a notable rate of complete responses. This presents olutasidenib as a significant treatment option in a challenging patient population. However, some risks, including differentiation syndrome and hepatotoxicity, were also noted.
Read more →RIGL▲ +7.1%on this newsshared move
Rigel Announces Second REZLIDHIA® (Olutasidenib) Publication in Blood Advances
Rigel Pharmaceuticals announced a new review article examining the clinical development of REZLIDHIA (olutasidenib) for treating relapsed/refractory acute myeloid leukemia (AML) with IDH1 mutations. The review highlights promising safety and efficacy data, citing durable patient responses and the potential for REZLIDHIA to become a market-leading therapy in this space. However, the review also notes significant side effects, including differentiation syndrome and hepatotoxicity. Further research is planned to evaluate its use in broader treatment settings.
Read more →RIGLRigel Announces Poster Presentation at the Upcoming 2023 American Society of Clinical Oncology Annual Meeting
Rigel Pharmaceuticals announced a poster presentation at the 2023 American Society of Clinical Oncology Annual Meeting showcasing its IRAK1/4 program. The presentation will focus on the ongoing Phase 1b clinical trial of R2891, an investigational IRAK1/4 inhibitor for patients with lower-risk myeloid dysplastic syndrome. Rigel has already completed enrollment for the first cohort of the trial, and enrollment for the second cohort is currently in progress. The meeting will take place in Chicago from June 2-6, 2023.
Read more →RIGLRigel to Present at the Jefferies 2023 Global Healthcare Conference
Rigel Pharmaceuticals, Inc. announced that CEO Raul Rodriguez will present at the Jefferies 2023 Global Healthcare Conference on June 7, 2023. The event will be held in New York and aims to provide insights into Rigel's advancements in therapies for hematologic disorders and cancer. Investors and interested parties will be able to access the live webcast through the company's website. This presentation underscores Rigel's focus on novel therapies and enhancing patient care.
Read more →RIGLRigel Reports First Quarter 2023 Financial Results and Provides Business Update First quarter 2023 Total Revenue of $26.1 million which includes TAVALISSE net product sales of $22.3 million and REZLIDHIA net product sale
Rigel Pharmaceuticals has reported its financial results for the first quarter of 2023, revealing total revenues of $26.1 million. This figure includes net product sales of $22.3 million from TAVALISSE and $1.5 million from REZLIDHIA. The company experienced a net loss of $13.5 million, which is an improvement over the previous year's loss of $27.4 million. Overall, Rigel's performance showcases growth in its hematology-oncology business, particularly in TAVALISSE sales, while navigating financial challenges associated with the development and sales of its products.
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2023 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. has announced it will report its first quarter 2023 financial results on May 2, 2023, followed by a live conference call and webcast. Senior management will discuss the financial results and provide a business update during the call. Participants can access the live conference call and the webcast, which will also be archived for 90 days. Rigel is focused on developing therapies for hematologic disorders and cancer.
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE net product sales of $21.9 million and REZLIDHIA
Rigel Pharmaceuticals announced its financial results for the fourth quarter and full year of 2022. Total revenues for the fourth quarter reached $51.3 million, driven by significant TAVALISSE sales, which saw a 25% increase compared to the previous year. The company also highlighted the launch of REZLIDHIA, a new treatment for acute myeloid leukemia. Despite these achievements, Rigel faced a net loss of $58.6 million for the year, which reflects ongoing challenges in managing expenses and costs.
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2022 Financial Results and Business Update
Rigel Pharmaceuticals, Inc. plans to report its fourth quarter and full year 2022 financial results on March 7, 2023. Following the announcement, a live conference call and webcast will be held to discuss these results and provide a business update. This event emphasizes Rigel's commitment to keeping investors informed. The webcast will also be archived for later access on the company's website.
Read more →RIGLRigel Announces Publication of REZLIDHIA™ (olutasidenib) Phase 2 Clinical Results in Blood Advances
Rigel Pharmaceuticals announced the publication of Phase 2 clinical results for REZLIDHIA (olutasidenib) in treating relapsed or refractory acute myeloid leukemia (R/R AML) with a specific IDH1 mutation. Results showed a 35% rate of complete remission and a median overall survival of 11.6 months. The therapy's safety profile was characterized as manageable, though differentiation syndrome and hepatotoxicity were noted as significant risks. REZLIDHIA was recently approved by the FDA and is seen as a crucial treatment option for patients with poor prognosis and limited alternatives.
Read more →RIGL▲ +7.3%on this news
National Comprehensive Cancer Network® Adds Newly Approved REZLIDHIA™ (olutasidenib) to Clinical Practice Guidelines in Oncology for Acute Myeloid Leukemia
Rigel Pharmaceuticals announced that its drug, REZLIDHIA (olutasidenib), has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for acute myeloid leukemia (AML). This targeted therapy is recommended for adult patients with relapsed/refractory AML who have an isocitrate dehydrogenase-1 (IDH1) mutation. The recognition by NCCN highlights the drug's efficacy and safety, although it comes with risks such as differentiation syndrome and hepatotoxicity that require careful patient monitoring.
Read more →RIGL▲ +12.8%on this news· ran to +31% by day 3
Rigel Pharmaceuticals Provides Business Update - REZLIDHIA U.S. FDA approval and commercial launch for the treatment of adult patients with relapsed or refractory AML with susceptible IDH1 mutation - Preliminary fourth q
Rigel Pharmaceuticals announced a business update highlighting the FDA approval and commercial launch of REZLIDHIA for treating adult patients with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. The company reported preliminary fourth-quarter revenues of approximately $51.3 million, driven by strong sales of TAVALISSE and initial sales of REZLIDHIA. However, safety concerns, including the risk of differentiation syndrome and hepatotoxicity, have emerged as critical points for monitoring as the new treatment enters the market.
Read more →RIGLRigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation
SOUTH SAN FRANCISCO, Calif., Dec. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that REZLIDHIA™ (olutasidenib) capsules are available in the U.S. by prescription for the treatment of adult patients with relapsed or refractory (R/R) acute mye
Read more →RIGL▲ +15.5%on this news· ran to +35% by day 1
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nas
Read more →RIGLRigel Announces U.S. FDA Approval of REZLIDHIA (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation REZLIDHIA is a potentiall y market-lea
Rigel Announces U.S. FDA Approval of REZLIDHIA (olutasidenib) for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with REZLIDHIA is a potentially market-leading, oral, mutant isocitrate dehydrogenase-1 (mIDH1) inhibitor Phase 2 registration
Read more →RIGL▲ +7.3%on this news
Rigel Announces Publication of Early Clinical Data of Olutasidenib in The Lancet Haematology
Early clinical data support olutasidenib's potential as a treatment for AML and MDS, in both the relapsed/refractory and newly diagnosed settings Olutasidenib showed durable remission in treatment-naïve and relapsed/refractory AML patients, with or without azacitidine PDUFA tar
Read more →RIGLRigel Reports Third Quarter 2022 Financial Results and Provides Business Update FDA review ongoing for olutasidenib NDA; preparations underway for potential launch Third quarter TAVALISSE net product sales of $19.2 milli
Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., Nov. 3, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2022, including sale
Read more →RIGLRigel Announces Five Poster Presentations at the Upcoming 64th American Society of Hematology Annual Meeting and Exposition
Updated interim analysis from Phase 2 registrational study highlights 35% of mIDH1 R/R AML patients who received olutasidenib achieved CR+CRh with a median duration of 25.9 months Presentations across the Company's commercial and clinical-stage hematology-oncology portfolio unde
Read more →RIGLRigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients
Rigel Announces Top-line Results from FOCUS Phase 3 Clinical Trial of Fostamatinib in High Risk Hospitalized COVID-19 Patients SOUTH SAN FRANCISCO, Calif., November 1, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced top-line efficacy and safety
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2022 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2022 financial results after market close on Thursday, November 3, 2022. Rigel senior management will follow the announcemen
Read more →RIGLRigel Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback --Announces Workforce Reduction
Provides Update on Plans for sNDA for wAIHA Program Following FDA Feedback --Announces Workforce Reduction-- SOUTH SAN FRANCISCO, Calif., October 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has received guidance from the U.S. Foo
Read more →RIGL▼ -7.7%on this news
Rigel to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference at 2:00 p.m. ET on Tuesday,
Read more →RIGL▲ +7.4%on this news· ran to +26% by day 3
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update Second quarter TAVALISSE net product sales of $18.6 million and total revenues of $29.8 million Expanded Rigel's hematology-oncology portfo
Rigel Reports Second Quarter 2022 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., August 2, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2022, including sales
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2022 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., July 26, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its second quarter 2022 financial results after market close on Tuesday, August 2, 2022. Rigel senior management will follow the announcement
Read more →RIGL▼ -60.2%on this news
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia Conference call and webcast to be held today at 8:00 a.m. Eastern Time
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia Conference call and webcast to be held today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., June 8, 2022 /PRNewswire/ -- Rigel Pharm
Read more →RIGLRigel Reports First Quarter 2022 Financial Results and Provides Business Update First quarter TAVALISSE net product sales of $16.2 million and total revenues of $16.7 million Topline data from FORWARD study, a pivotal, P
Rigel Reports First Quarter 2022 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 3, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2022, including sales of
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2022 Financial Results and Business Update
– Key Opinion Leader and FORWARD trial investigator, Caroline Piatek, M.D., to join Rigel management to share experience and insight treating patients with wAIHA – SOUTH SAN FRANCISCO, Calif., April 26, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announ
Read more →RIGLRigel Announces Publication of Data from Phase 2 Clinical Study of Fostamatinib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia in the American Journal of Hematology
SOUTH SAN FRANCISCO, Calif., March 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the publication of data in the American Journal of Hematology from the open label, multicenter, Phase 2 clinical study of fostamatinib in adults with warm antibod
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Fourth quarter total revenues of $20.4 million; full year total revenues of $149.2 million On track to report topline data fr
Rigel Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Fourth quarter total revenues of $20.4 million; full year total revenues of $149.2 million On track to report topline data from Phase 3 pivotal trials of fostamatinib in warm autoimmune
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022. Rigel senior management will follow the an
Read more →RIGLRigel Pharmaceuticals Provides Business Update TAVALISSE preliminary 2021 net product sales of approximately $63.0 million Topline data from Phase 3 clinical trial in warm autoimmune hemolytic anemia (wAIHA) expected in
Rigel Pharmaceuticals Provides Business SOUTH SAN FRANCISCO, Calif., January 10, 2022 - Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update including preliminary 2021 full-year total revenue, the status of the Phase 3 study in COVID-19, and upcoming cat
Read more →RIGLRigel to Present at the J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 40th Annual J.P. Morgan Healthcare Con
Read more →RIGLFostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that its collaboration partner, Kissei Pharmaceutical Co., Ltd. ("Kissei"), has released positive topline results from its Phase 3 clinical trial in Japan evalua
Read more →RIGLRigel Appoints Kamil Ali-Jackson to Board of Directors
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Kamil Ali-Jackson to the company's Board of Directors. Ms. Ali-Jackson brings nearly four decades of biopharmaceutical industry experience t
Read more →RIGLRigel Sharpens Focus on Its Advanced Portfolio Opportunities
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced plans to exit early-stage research and focus resources on its mid to late-stage development programs and its commercial efforts. The strategy will strengthen Rigel
Read more →RIGLRigel to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 9, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Dean Schorno, the company's chief financial officer, will participate in the following virtual investor conferences in November: Jefferies Virtual London Heal
Read more →RIGLRigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Completed enrollment of FORWARD Phase 3 trial of fostamatinib in patients with warm autoimmune hemolytic anemia (wAIHA), topline data expe
Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., November 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter ended September 30, 2021, including
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2021 financial results after market close on Tuesday, November 2, 2021. Rigel senior management will follow the announcement
Read more →RIGLRigel to Participate in Three Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, and Dean Schorno, the company's chief financial officer, will participate in the followi
Read more →RIGL▲ +8.2%on this newsshared move
Data from NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients Published in Clinical Infectious Diseases
SOUTH SAN FRANCISCO, Calif., Sept. 1, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the publication of results from a Phase 2 clinical trial evaluating the safety of fostamatinib for the treatment of hospitalized patients with COVID-19, in Clini
Read more →RIGL▼ -9.9%on this news
Rigel Pharmaceuticals Provides Update on COVID-19 Program -- FDA declines to issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults -- -- Rigel's COVID-19 program continue
Rigel Pharmaceuticals Provides Update on COVID-19 -- FDA declines to issue emergency use authorization for fostamatinib for the treatment of COVID-19 in hospitalized adults -- -- Rigel's COVID-19 program continues to actively enroll patients and will provide a robust data se
Read more →RIGL▼ -6%on this news
Rigel Reports Second Quarter 2021 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Aug. 3, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter ended June 30, 2021, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., July 27, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2021 financial results after market close on Tuesday, August 3, 2021. Rigel senior management will follow the announcement w
Read more →RIGLNew TAVALISSE® Data Analyses To Be Presented at International Society on Thrombosis and Haemostasis (ISTH) 2021 Congress
SOUTH SAN FRANCISCO, Calif., July 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data from its clinical development program for TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in two presentations at the upcomi
Read more →RIGLFostamatinib Selected for NIH ACTIV-4 COVID-19 Clinical Trial
SOUTH SAN FRANCISCO, Calif., June 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib, the Company's novel oral spleen tyrosine kinase (SYK) inhibitor, has been selected for a National Institutes of Health (NIH) ACTIV-4 (Accelera
Read more →RIGLRigel to Present at the Jefferies Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual Healthcare Conference
Read more →RIGLRigel Appoints Alison L. Hannah, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Alison L. Hannah, M.D. to its Board of Directors. Dr. Hannah brings over three decades of pharmaceutical industry experience to Rigel, includ
Read more →RIGLRigel Reports First Quarter 2021 Financial Results and Provides Business Update - Reported positive topline results of fostamatinib in Phase 2 clinical trial in hospitalized patients with COVID-19 - Net product sales of
Rigel Reports First Quarter 2021 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., May 5, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2021, including sales of
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2021 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., April 28, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021. Rigel senior management will follow the announcement wi
Read more →RIGLPositive Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 Broad and consistent improvement in clinical outcomes including serious adverse e
Topline Data Shows Fostamatinib Meets Primary Endpoint of Safety in Phase 2 Clinical Trial in Hospitalized Patients with COVID-19 and consistent improvement in clinical outcomes including serious adverse events, mortality, ordinal scale assessment and number of days plans to sh
Read more →RIGLRigel Announces Closing of Strategic Collaboration with Lilly
SOUTH SAN FRANCISCO, Calif., April 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the successful closing of its license agreement with Eli Lilly and Company (Lilly), following the expiration of the waiting period under the Hart-Scott Rodino Ant
Read more →RIGLRigel Announces Completion of Patient Enrollment for NIH/NHLBI-Sponsored Phase 2 Trial of Fostamatinib in Hospitalized COVID-19 Patients
SOUTH SAN FRANCISCO, Calif., March 11, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the completion of patient enrollment in a multi-center Phase 2 clinical trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) i
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update - Fourth quarter total revenues of $18.5 million; full year total revenues of $108.6 million - Rigel will receive an upfront
Rigel Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., March 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and full year ended Dec
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2020 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2020 financial results after market close on Tuesday, March 2, 2021. Rigel senior management will follow the an
Read more →RIGLRigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients
SOUTH SAN FRANCISCO, Calif., Jan. 29, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced it has been awarded $16.5 million by the U.S. Department of Defense's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defe
Read more →RIGLRigel Pharmaceuticals Provides Business Update TAVALISSE preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41% U.S. FDA awards Fast Track designation to TAVALISSE for warm au
Rigel Pharmaceuticals Provides Business preliminary 2020 net product sales of approximately $61.7 million, a year-over-year increase of 41% FDA awards Fast Track designation to TAVALISSE for warm autoimmune hemolytic anemia data from NIH Phase 2 clinical trial in COVID-19 expe
Read more →RIGLRigel to Present at the 39th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the 39th Annual J.P. Morgan Virtual Healthc
Read more →RIGLRigel Announces Two Posters Highlighting TAVALISSE at the 62nd ASH Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Dec. 4, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be presented in two poster presentations at the 62nd American Society of Hematolog
Read more →RIGLRigel Finalizes the Study Design of its Ongoing Phase 3 Clinical Trial of Fostamatinib in Warm Autoimmune Hemolytic Anemia
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has reached agreement with the U.S. Food and Drug Administration (FDA) on the final design of its FORWARD study, a pivotal Phase 3 clinical trial of fosta
Read more →RIGLRigel to Present at the Jefferies Virtual London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Virtual London Healthcare Co
Read more →RIGLRigel Reports Third Quarter 2020 Financial Results and Provides Business Update Third quarter total revenues of $18.4 million Net product sales of $16.3 million, a 39% year-over-year increase Launching Phase 3 clinical t
Rigel Reports Third Quarter 2020 Financial Results and Provides Business Update Third quarter total revenues of $18.4 Net product sales of $16.3 million, a 39% year-over-year increase Launching Phase 3 clinical trial of fostamatinib in COVID-19 patients Conference call and
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2020 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its third quarter 2020 financial results after market close on Thursday, November 5, 2020. Rigel senior management will follow the announcemen
Read more →RIGLRigel Announces First Patients Enrolled in NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
SOUTH SAN FRANCISCO, Calif., Oct. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced enrollment of the first patients in a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor, for t
Read more →RIGLRigel Announces NIH/NHLBI-Sponsored Trial of Fostamatinib in Hospitalized COVID-19 Patients in Collaboration with Inova
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the start of a multicenter, Phase 2 trial to evaluate the safety of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of hospitali
Read more →RIGLRigel to Present at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at two virtual investor conferences in September. Investor Present
Read more →RIGLRigel to Participate in Citi
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2020 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion on COVID-19 during Citi's 15th Annual BioPha
Read more →RIGLRigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in
Rigel Reports Second Quarter 2020 Financial Results, Provides Business Update, and Overviews COVID-19 Program Second quarter net product sales of $15.0 million, a year-over-year increase of 47% University of Amsterdam in vitro studies showed fostamatinib blocked macrophage
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2020 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., July 28, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2020 financial results after market close on Tuesday, August 4, 2020. Rigel senior management will follow the announcement w
Read more →RIGLRigel Announces Post-hoc Data Analysis of TAVALISSE® in Adult Patients with Immune Thrombocytopenia Published in the British Journal of Haematology
SOUTH SAN FRANCISCO, Calif., July 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that a paper presenting a post-hoc data analysis of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, as well as accompanying commentary have been publishe
Read more →RIGLRigel Announces Investigator-Sponsored Trial of Fostamatinib in Patients with COVID-19 Pneumonia
SOUTH SAN FRANCISCO, Calif., July 14, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of an investigator-sponsored trial (IST) being conducted by Imperial College London to evaluate the efficacy of fostamatinib, its oral spleen tyros
Read more →RIGLRigel Announces Availability of TAVLESSE® (Fostamatinib Disodium Hexahydrate) in Europe
SOUTH SAN FRANCISCO, Calif., July 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Grifols S.A., its collaborative partner in Europe, has launched TAVLESSE® in Germany and the United Kingdom. It was approved by the European Commission in Jan
Read more →RIGLRigel to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 17, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the BMO 2020 Prescriptions for Success Healthcare Virtual
Read more →RIGLRigel to Present Poster Highlighting TAVALISSE at the Virtual Edition of the 25th European Hematology Association (EHA) Annual Congress
SOUTH SAN FRANCISCO, Calif., June 11, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets will be highlighted in a presentation at the Virtual Edition of the 25th EHA Annual Co
Read more →RIGLRigel to Present Four Posters Highlighting IRAK1/4 Inhibitor at the EULAR 2020 E-Congress
SOUTH SAN FRANCISCO, Calif., June 3, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that data related to R835, the company's investigational IRAK1/4 inhibitor, will be presented in two oral and two poster presentations at the European League Again
Read more →RIGLRigel Reports First Quarter 2020 Financial Results and Provides Business Update
SOUTH SAN FRANCISCO, Calif., May 5, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2020, including sales of TAVALISSE® (fostamatinib disodium hexahydrate) tablets, for the treatment of adults
Read more →RIGLRigel Reports First Quarter 2020 Financial
Rigel Reports First Quarter 2020 Financial Results and Provides Business Update First quarter net product sales of $12.7 million and collaboration revenues of $43.1 million 41 patients enrolled in pivotal Phase 3 clinical trial in warm AIHA Received $10.0 million in funding
Read more →RIGLRigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., May 1, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that, due to public health and safety concerns related to the coronavirus ("COVID-19") pandemic, recommendations and orders from federal, state and local authoritie
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update
SOUTH SAN FRANCISCO, Calif., April 27, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2020 financial results after market close on Tuesday, May 5, 2020. Rigel senior management will follow the announcement with
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Fourth quarter total revenues of $15.4 million; full year total revenues of $59.3 million Fourth quarter net product sales of
Rigel Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Fourth quarter total revenues of $15.4 million; full year total revenues of $59.3 million Fourth quarter net product sales of $13.8 million; full year net product sales of $43.8 mi
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2019 financial results after market close on Thursday, February 27, 2020. Rigel senior management will follow t
Read more →RIGLRigel Pharmaceuticals Provides Business
Rigel Pharmaceuticals Provides Business SOUTH SAN FRANCISCO, Calif., January 13, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, including preliminary product revenue and total TAVALISSE (fostamatinib disodium hexahydrate) bot
Read more →RIGLRigel to Present at the 38th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Jan. 9, 2020 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Thursday,
Read more →RIGLRigel Announces Chief Commercial Officer Transition
SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that Eldon Mayer has resigned from his position as chief commercial officer effective December 23, 2019, to pursue an opportunity with an emerging company. "We
Read more →RIGLRigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe SOUTH SAN FRANCISCO, November 15, 2019 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee fo
Read more →RIGLRigel to Present at Jefferies 2019 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 London Healthcare Conference on Thursda
Read more →RIGLRigel Announces Upcoming Data Presentations at the 61st ASH Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 7, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that data related to TAVALISSE® (fostamatinib disodium hexahydrate) tablets has been accepted for two poster presentations at the 61st American Society of Hematol
Read more →RIGLRigel Announces Third Quarter 2019 Financial Results Net sales of TAVALISSE increased 15% quarter over quarter to $11.7 million Advances development pipeline with new RIP1 inhibitor program initiating a Phase 1 study and
Rigel Announces Third Quarter 2019 Financial Results Net sales of TAVALISSE increased 15% quarter over quarter to $11.7 million Advances development pipeline with new RIP1 inhibitor program initiating a Phase 1 study and positive in-human data from IRAK1/4 inhibitor program C
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2019 financial results after market close on Tuesday, November 5, 2019. Rigel senior management will follow the announcement
Read more →RIGLRigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call TAVALISSE net product sales increased 15% quarter over quarter to $11.7 million Positive results from IRAK1/4 Proof-of-Mechanism study in hu
Rigel Pharmaceuticals Provides Business Update Prior to Investor & Analyst Call TAVALISSE net product sales increased 15% quarter over quarter to $11.7 million Positive results from IRAK1/4 Proof-of-Mechanism study in humans Announced new RIP1 inhibitor program, lead molecule
Read more →RIGLRigel Receives Positive Trend Vote from CHMP for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe
SOUTH SAN FRANCISCO, Calif., Oct. 18, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), has adopted a positive trend vote on the Marketing Authoriz
Read more →RIGLRigel to Host Investor and Analyst Call on October 23, 2019
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced that it will host a conference call and webcast for investors and analysts on Wednesday, October 23, 2019, at 10:00am Eastern Time. Members of Rigel's senior mana
Read more →RIGLRigel Secures Credit Facility for Up to $60 Million
SOUTH SAN FRANCISCO, Oct. 2, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into a $60 million term loan credit facility with MidCap Financial ("MidCap"). At closing, $10 million was funded to Rigel in an initial tranche. The f
Read more →RIGLRigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ( Kissei ), has initiated ...
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. ("Kissei"), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult
Read more →RIGLRigel's CEO to Participate in Panel Discussion at Citi's 14th Annual Biotech Conference Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to...
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to participate in a panel discussion at Citi's 14th Annual Biotech Conferenc
Read more →RIGLRigel Announces Second Quarter 2019 Financial Results and Provides Business Update TAVALISSE net product sales increased 26% quarter over quarter to $ 10. 2 million First patients enrolled in Phase 3 pivotal trial of TAV
Rigel Announces Second Quarter 2019 Financial Results and Provides Business Update TAVALISSE net product sales increased 26% quarter over quarter to $10.2 million First patients enrolled in Phase 3 pivotal trial of TAVALISSE in warm autoimmune hemolytic anemia (AIHA) Conferenc
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, July 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2019 financial results after market close on Tuesday, August 6, 2019. Rigel senior management will follow the announcement with a li
Read more →RIGLRigel to Present Two Posters Highlighting Fostamatinib at the 24ᵗʰ Congress of the European Hematology Association (EHA)
SOUTH SAN FRANCISCO, June 13, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present data on fostamatinib disodium hexahydrate (fostamatinib) in two posters at the 24th Congress of the European Hematology Association (EHA) in Amsterda
Read more →RIGLRigel to Present at Jefferies 2019 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2019 Healthcare Conference in New York City o
Read more →RIGLRigel Enrolls First Patient in Phase 3 Clinical Trial of Fostamatinib Disodium Hexahydrate in Warm Autoimmune Hemolytic Anemia
SOUTH SAN FRANCISCO, Calif., May 16, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of fostamatinib disodium hexahydrate (fostamatinib) in warm antibody autoimmune hemolyt
Read more →RIGLRigel Announces First Quarter 2019 Financial Results and Provides Company Update TAVALISSE net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million, includin
Rigel Announces First Quarter 2019 Financial Results and Provides Company Update TAVALISSE net product sales of $8.1 million on 1,019 bottles, a 10% increase quarter-over-quarter Total revenues of $12.6 million, including $4.6 million from collaborations Opened clinical trial
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2019 Financial Results and Company Update
SOUTH SAN FRANCISCO, Calif., April 30, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2019 financial results after market close on Tuesday, May 7, 2019. Rigel senior management will follow the announcement with
Read more →RIGLRigel Welcomes Jane Wasman to Board of Directors
SOUTH SAN FRANCISCO, Calif., March 26, 2019 /PRNewswire/ --Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Jane Wasman to its board of directors. Ms. Wasman is a strategic leader with over 20 years of experience in the biopharma industry working w
Read more →RIGLRigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Fourth quarter total revenues of $37.9 million; full year total revenues of $44.5 million Fourth quarter net product sales of
Rigel Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update Fourth quarter total revenues of $37.9 million; full year total revenues of $44.5 million Fourth quarter net product sales of $7.3 million; full year net product sales of $13.9 millio
Read more →RIGLRigel Pharmaceuticals Enters Collaboration and License Agreement with Grifols, S.A. to Commercialize Fostamatinib in Europe
SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has entered into an exclusive license and supply agreement with Spain-based Grifols, S.A (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS) to commercialize fostamatini
Read more →RIGLRigel Pharmaceuticals Provides Business Update Reports 1,794 total bottles of TAVALISSE TM (fostamatinib disodium hexahydrate) sold in 2018
Rigel Pharmaceuticals Provides Business Update Reports 1,794 total bottles of TAVALISSE TM (fostamatinib disodium hexahydrate) sold in 2018 SOUTH SAN FRANCISCO, Calif., Jan. 7, 2019 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today provided a business update, includ
Read more →RIGLRigel to Present at the 37th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Jan. 3, 2019 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and CEO, is scheduled to present a company overview at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January
Read more →RIGLRigel to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York City
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the BMO Capital Markets 2018 P
Read more →RIGLRigel Announces Third Quarter 2018 Financial Results and Provides Company Update Reports TAVALISSE TM (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM East
Rigel Announces Third Quarter 2018 Financial Results and Provides Company Update Reports TAVALISSETM (fostamatinib disodium hexahydrate) net product sales of $4.9 million Conference call and webcast today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif., November 6, 2018 /PR
Read more →RIGLRigel to Present Data on Fostamatinib in Three Presentations at the 60th American Society of Hematology Annual Meeting & Exposition
SOUTH SAN FRANCISCO, Calif., Nov. 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that two-year safety and efficacy data from its FIT Phase 3 extension study (FIT3) for the treatment of thrombocytopenia in adult patients with chronic immune thr
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2018 financial results after market close on Tuesday, November 6, 2018. Rigel senior management will follow the announcement
Read more →RIGLRigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it had entered into an exclusive license and supply agreement with Kissei Pharmaceutical Co., Ltd. ("Kissei") to develop and commercialize TAVALISSE™ in all
Read more →RIGLRigel Receives EMA Validation of the Marketing Authorization Application for Fostamatinib Disodium Hexahydrate in Chronic Immune Thrombocytopenia (ITP) in Adult Patients
SOUTH SAN FRANCISCO, Calif., Oct. 11, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for fostamatinib in adult chronic immune thrombocytopenia. Th
Read more →RIGLRigel to Host Investor & Analyst Day in New York City on October 4, 2018
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will host an investor and analyst day event on Thursday, October 4, 2018 from 12:00pm to 2:30pm Eastern Time in New York City. Members of Rigel's managem
Read more →RIGLRigel to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Global Healthcare Conference i
Read more →RIGLRigel to Present at the 20th Annual Global Investment Conference in New York City
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's executive vice president and chief financial officer, is scheduled to present a company overview at the 20th Annual Rodman & Rens
Read more →RIGLRigel Announces Second Quarter 2018 Financial Results and Provides Company Update $1.8 Million in Net Product Sales for TAVALISSE (fostamatinib disodium hexahydrate) Conference Call and Webcast Today at 5:00PM Eastern Ti
Rigel Announces Second Quarter 2018 Financial Results and Provides Company Update $1.8 Million in Net Product Sales for TAVALISSE (fostamatinib disodium hexahydrate) Conference Call and Webcast Today at 5:00PM Eastern Time SOUTH SAN FRANCISCO, Calif., August 8, 2018 /PRNewswir
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that it will report its second quarter 2018 financial results after market close on Wednesday, August 8, 2018. Rigel senior management will follow the announcement
Read more →RIGLRigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases
SOUTH SAN FRANCISCO, Calif., June 26, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has initiated a Phase 1 study to assess safety, tolerability, pharmacokinetics and pharmacodynamics of R835 in healthy subjects. Rigel selected R835, a pr
Read more →RIGLRigel Announces Poster Presentations at FOCIS Annual Meeting
SOUTH SAN FRANCISCO, Calif., June 20, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dr. Anne-Marie Duliege, Chief Medical Officer, will be presenting two posters on fostamatinib at the Federation of Clinical Immunology Societies (FOCIS) Annu
Read more →RIGLRigel To Present Phase 2 Results for Fostamatinib in Autoimmune Hemolytic Anemia at EHA
SOUTH SAN FRANCISCO, Calif., June 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting an oral presentation on the Phase 2 Stage 1 interim results for fostamatinib in patients with warm antibody hemolytic anemia (AIHA) at
Read more →RIGLRigel to Present at Jefferies 2018 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 31, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies Global Healthcare Conference
Read more →RIGLRigel Appoints Dean Schorno as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif., May 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has appointed Dean Schorno, CPA as Executive Vice President and Chief Financial Officer (CFO). Formerly the CFO and Head of Operations at 23andMe, Inc., Mr.
Read more →RIGLRigel Announces Availability of TAVALISSE™ (fostamatinib disodium hexahydrate) in the U.S.
SOUTH SAN FRANCISCO, Calif., May 29, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that TAVALISSE™ (fostamatinib disodium hexahydrate) is available by prescription for the treatment of thrombocytopenia in adult patients with chronic immune throm
Read more →RIGLRigel Announces First Quarter 2018 Financial Results and Provides Company Update Rigel Expected to Launch TAVALISSE (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:
Rigel Announces First Quarter 2018 Financial Results and Provides Company Update Rigel Expected to Launch TAVALISSE (fostamatinib disodium hexahydrate) in the U.S. in late May 2018 Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. May 1, 201
Read more →RIGLTAVALISSE™ (fostamatinib disodium hexahydrate) Phase 3 Data Published in the American Journal of Hematology Describes Pivotal Data and Overall Response Rate Versus Placebo
SOUTH SAN FRANCISCO, Calif., April 30, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the American Journal of Hematology has published positive results from the Fostamatinib in Thrombocytopenia (FIT) Phase 3 clinical program of TAVALISSE™ (fos
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., April 24, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2018 financial results after market close on Tuesday, May 1, 2018. Rigel senior management will follow the announcement with
Read more →RIGLRigel Announces Pricing Of Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., April 19, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of its previously announced underwritten public offering of 16,000,000 shares of its common stock, offered at a price of $3.90 per share to the publi
Read more →RIGLRigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients
SOUTH SAN FRANCISCO, Calif., April 17, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) approved TAVALISSE™ (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adult patients w
Read more →RIGLcompletely and with the understanding that our actual future results may be materially different from what we expect. We hereby qualify all of our forward-looking statements by these cautionary statements. Except as requ
Unless otherwise indicated or the context requires otherwise, references in this Exhibit 99.1 to Rigel, the company, we, us and our refer to Rigel Pharmaceuticals, Inc. The name Rigel Pharmaceuticals and our logo are our trademarks. All other trademarks, trade names or service ma
Read more →RIGLRigel Makes Statement Regarding Website Error
SOUTH SAN FRANCISCO, Calif., April 12, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), reported that due to an error by the external host of its investor relations website, inaccurate information was displayed regarding the U.S. Food and Drug Administration's (FD
Read more →RIGLRigel Announces Topline Data from Proof-of-Concept Phase 2 Study of Fostamatinib in IgA Nephropathy
SOUTH SAN FRANCISCO, Calif., April 3, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL), today announced topline data from its proof-of-concept Phase 2 study of fostamatinib in patients with IgA nephropathy (IgAN), an orphan autoimmune disease of the kidneys. The tri
Read more →RIGLRigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time
Rigel Announces Fourth Quarter and Year End 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time SOUTH SAN FRANCISCO, Calif., March 6, 2018 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial re
Read more →RIGLRigel Announces Two Fostamatinib Presentations at the 4th Biennial Summit of the Thrombosis & Hemostasis Societies of North America
SOUTH SAN FRANCISCO, Calif., March 1, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that fostamatinib data from its FIT Phase 3 extension study (FIT3) in patients with chronic immune thrombocytopenia (ITP) and preliminary data from its SOAR Phas
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2017 financial results after market close on Tuesday, March 6, 2018. Rigel senior management will follow the an
Read more →RIGLRigel Pharmaceuticals, Inc. Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Feb. 16, 2018 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced that on January 24, 2018 the Compensation Committee of Rigel's Board of Directors approved the grant of inducement stock options to purchase an aggregate of 30,000 shar
Read more →RIGLRigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference
Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib in AIHA at the 36th Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Jan. 4, 2018 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the c
Read more →RIGLRigel Announces Departure of Chief Financial Officer Launches Search for Chief Financial Officer with Commercial-Stage Expertise
Rigel Announces Departure of Chief Financial Officer Launches Search for Chief Financial Officer with Commercial-Stage Expertise SOUTH SAN FRANCISCO, Calif., Dec. 15, 2017 /PRNewswire/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the resignation of Ryan Maynard, e
Read more →RIGLRigel to Present One-Year Efficacy and Safety Results for Fostamatinib in ITP at the 2017 American Society of Hematology Annual Meeting
SOUTH SAN FRANCISCO, Calif., Dec. 8, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune thrombocytopenia (ITP) will be
Read more →RIGLRigel Announces Third Quarter 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif.
Rigel Announces Third Quarter 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. November 7, 2017 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quart
Read more →RIGLRigel Welcomes Gregg Lapointe to Board of Directors
SOUTH SAN FRANCISCO, Calif., Nov. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Gregg Lapointe, CPA, MBA has been appointed to Rigel's board of directors. Currently the chief executive officer (CEO) and co-founder of Cerium Pharmaceuticals
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter financial results after market close on Tuesday, November 7, 2017. Rigel senior management will follow the announcement with
Read more →RIGLRigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares
SOUTH SAN FRANCISCO, Calif., Oct. 10, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL) today announced the closing of its previously announced underwritten public offering of 20,815,000 shares of its common stock at a price to the public of $3.35 per share, which
Read more →RIGLFostamatinib Meets Pre-Specified Primary Endpoint in Stage 1 of Autoimmune Hemolytic Anemia (AIHA) Phase 2 Study
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the company recently completed enrollment of Stage 1 of its Phase 2, open-label, multi-center, two-stage study of its investigational drug fostamatinib for the
Read more →RIGLRigel Announces Proposed Public Offering Of Common Stock
SOUTH SAN FRANCISCO, Calif., Oct. 3, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it intends to offer and sell up to $40,000,000 of shares of its common stock in an underwritten public offering. Rigel expects to grant the underwriters a 30-
Read more →RIGLRigel Provides Update on FDA Review of Fostamatinib for ITP
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that during the company's mid-cycle meeting with the U.S. Food and Drug Administration (FDA) the FDA indicated that, at this point, it is not planning to hold an On
Read more →RIGLRigel to Present at Cantor Fitzgerald Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Cantor Fitzgerald Global Healthcare C
Read more →RIGLRigel Welcomes Brian Kotzin, M.D. to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Brian L. Kotzin, M.D. has been appointed to Rigel's board of directors. A well-respected former professor and clinical researcher, Dr. Kotzin brings to Rigel'
Read more →RIGLRigel Announces Second Quarter 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif.
Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. August 1, 2017 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quart
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., July 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter financial results after market close on Tuesday, August 1, 2017. Rigel senior management will follow the announcement with a
Read more →RIGLRigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress
SOUTH SAN FRANCISCO, Calif., June 22, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persistent imm
Read more →RIGLFDA Accepts Rigel
SOUTH SAN FRANCISCO, Calif., June 19, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced the U.S. Food and Drug Administration (FDA) has filed its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or
Read more →RIGLRigel to Present at Jefferies 2017 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 1, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2017 Global Healthcare Conference on Wednesda
Read more →RIGLRigel Announces First Quarter 2017 Financial Results and Provides Company Update - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif.
Rigel Announces First Quarter 2017 Financial Results and Provides Company Update - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif. May 2, 2017 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarte
Read more →RIGLRigel Announces Tavalisse™ as Proprietary Name for Fostamatinib in the United States
SOUTH SAN FRANCISCO, Calif., April 27, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name Tavalisse™ for the company's investigational product candidate, f
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2017 Financial Results
SOUTH SAN FRANCISCO, Calif., April 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2017 financial results after market close on Tuesday, May 2, 2017. Rigel senior management will follow the announcement with
Read more →RIGLRigel Submits New Drug Application to FDA for Fostamatinib in Chronic ITP
SOUTH SAN FRANCISCO, Calif., April 17, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for fostamatinib in patients with chronic and persistent immune
Read more →RIGLRigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif.
Rigel Announces Fourth Quarter 2016 and Year End 2016 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. March 7, 2017 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2016 financial results after market close on Tuesday, March 7, 2017. Rigel senior management will follow the an
Read more →RIGLFostamatinib Study Results Continue to Trend Positive
SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced updates from the clinical program of fostamatinib in patients with chronic immune thrombocytopenic purpura (ITP). Previously released results from the FIT Phase 3
Read more →RIGLRigel Provides Business Updates and Preliminary Data in IgA Nephropathy
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financial overview at the upcoming
Read more →RIGLRigel to Present at Jefferies 2016 London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2016 London Healthcare Confe
Read more →RIGLRigel Announces Third Quarter 2016 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif.
Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. November 1, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quart
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 28, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2016 financial results after the stock market closes on Tuesday, November 1, 2016. Members of Rigel's senior management will
Read more →RIGLRigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP Conference call and webcast today at 8:00 AM Eastern Time
Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP Conference call and webcast today at 8:00 AM Eastern Time SOUTH SAN FRANCISCO, Calif., October 20, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) toda
Read more →RIGLRigel Expands Leadership Team in Research and Business Development
SOUTH SAN FRANICSCO, Calif., Oct. 7, 2016 /PRNewswire/ -- Rigel Pharmaceuticals (Nasdaq: RIGL) today announced the appointment of two company veterans to leadership roles that will impact Rigel's newly refocused small molecule R&D effort targeting immunology and oncology diseases
Read more →RIGLRigel Restructures to Focus on Fostamatinib Commercialization Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires SOUTH SAN FRANCISCO, Calif .
Rigel Restructures to Focus on Fostamatinib Commercialization Hires Eldon Mayer as first Chief Commercial Officer, Founder Donald Payan Retires SOUTH SAN FRANCISCO, Calif., September 15, 2016 Rigel Pharmaceuticals (Nasdaq: RIGL) today announced plans to build a commercial organ
Read more →RIGLLOGO] Rigel Conference Call FIT Phase 3 Study in ITP
Rigel Conference Call FIT Phase 3 Study in ITP August 30, 2016 5:00am PT / 8:00am ET Agenda Safe Harbor Statement D. Vance Introduction and Overview R. Rodriguez FIT 1 Phase 3 Results A. Duliege FIT 1 Phase 3 Commentary J. Bussel Q&A Safe Harbor Statement In the conference call
Read more →RIGLRigel's Fostamatinib Meets Primary Endpoint in Phase 3 Study in Chronic ITP Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary...
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, met the primary endpoint in the first of two double-blind studies in the FIT Phase 3 clinical p
Read more →RIGLRigel Announces Press Release and Conference Call Schedule on Tuesday, August 30, 2016
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) announced that the company will announce results of the first of two FIT Phase 3 studies of fostamatinib for patients with immune thrombocytopenia (ITP), at 7:00 a.m. Eastern Time
Read more →RIGLRigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif.
Rigel Announces Second Quarter 2016 Financial Results and Provides Portfolio Update Conference Call and Webcast Today at 5:00 PM Eastern Time South San Francisco, Calif. August 2, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second qua
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., July 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2016 financial results after market close on Tuesday, August 2, 2016. Rigel senior management will follow the announcement w
Read more →RIGLRigel to Present at Jefferies 2016 Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 2, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Jefferies 2016 Healthcare Conference in New York City o
Read more →RIGLRigel to Present at Upcoming American Association of Immunologists (AAI) Annual Meeting
SOUTH SAN FRANCISCO, Calif., May 5, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will present three scientific posters at the American Association of Immunologists (AAI) meeting in Seattle, Washington from May 13-17, 2016. The posters pr
Read more →RIGLRigel Announces First Quarter 2016 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif.
Rigel Announces First Quarter 2016 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif. May 3, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2016. We
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2016 Financial Results
SOUTH SAN FRANCISCO, Calif., April 26, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2016 financial results after market close on Tuesday, May 3, 2016. Rigel senior management will follow the announcement with
Read more →RIGLRigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference
SOUTH SAN FRANCISCO, Calif., April 12, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will present three scientific posters at the American Association of Cancer Research meeting in New Orleans, Louisiana from April 16 - 20, 2016. The poste
Read more →RIGLRigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., April 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromb
Read more →RIGLRigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program
Rigel Names Anne-Marie Duliege, M.D., M.S. As Chief Medical Officer Elliott Grossbard, M.D. Retires; Continues Advising on Fostamatinib in the ITP Program SOUTH SAN FRANCISCO, Calif., March 8, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of An
Read more →RIGLRigel Announces Fourth Quarter and Year End 2015 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2015 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time - South San Francisco, Calif. March 8, 2016 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year
Read more →RIGLRigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2015 Financial Results
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., March 1, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2015 financial results after market close on Tuesday, March 8, 2016. Rigel senior
Read more →RIGLRigel to Present at Cowen and Company 36th Annual Health Care Conference
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 29, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Cowen and Company 36th An
Read more →RIGLRigel Initiates Phase 2 Clinical Trial Of Fostamatinib In Autoimmune Hemolytic Anemia
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Feb. 25, 2016 /PRNewswire/ -- Rigel Pharmaceuticals Inc. (Nasdaq: RIGL) today announced that it has initiated a Phase 2 clinical trial to evaluate fostamatinib, its oral SYK inhibitor, as a potential treatment for autoimmu
Read more →RIGLRigel Completes Enrollment of First Phase 3 Study of Fostamatinib in ITP (FIT)
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 28, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) today announced that the first of two Phase 3 clinical studies of fostamatinib in immune thrombocytopenic purpura (ITP) completed patient enrollment
Read more →RIGLRigel Reviews Recent Progress and Announces Presentation at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 7, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present a review of products in development and a financ
Read more →RIGLRigel Announces Third Quarter 2015 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time
Rigel Announces Third Quarter 2015 Financial Results - Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif. November 3, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended
Read more →RIGLRigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
Rigel Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., Oct. 27, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2015 financial results after market close on Tuesday, November 3, 2015. Rigel senior management
Read more →RIGLRigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, Inc., and Rigel have entered into an exclusive, worldwi
Read more →RIGLRigel Granted Orphan Drug Designation for Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., Sept. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is curre
Read more →RIGLRigel Announces Second Quarter 2015 Financial Results - Conference Call and Webcast Today at 4:30 PM Eastern Time
Rigel Announces Second Quarter 2015 Financial Results - Conference Call and Webcast Today at 4:30 PM Eastern Time - SOUTH SAN FRANCISCO, Calif. August 4, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended
Read more →RIGLRigel Announces Conference Call and Webcast to Report Second Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., July 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter 2015 financial results after market close on Tuesday, August 4, 2015. Rigel senior management will follow the announcement w
Read more →RIGLRigel Welcomes Keith A. Katkin to Board of Directors
SOUTH SAN FRANCISCO, Calif., June 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Keith A. Katkin, president and chief executive officer of Avanir Pharmaceuticals, has been appointed to Rigel's board of directors. Mr. Katkin brings to Rige
Read more →RIGLRigel to Present at Jefferies 2015 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 28, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, is scheduled to present a company overview at the Jefferies 2015 Global Healthcare Confer
Read more →RIGLRigel Announces First Quarter 2015 Financial Results - Conference Call and Webcast Today at 4:30 PM Eastern Time - South San Francisco, Calif.
Rigel Announces First Quarter 2015 Financial Results - Conference Call and Webcast Today at 4:30 PM Eastern Time - South San Francisco, Calif. May 7, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2015. For
Read more →RIGLRigel Announces Conference Call and Webcast to Report First Quarter 2015 Financial Results and Pipeline Update
SOUTH SAN FRANCISCO, Calif., April 30, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its first quarter 2015 financial results after market close on Thursday, May 7, 2015. Rigel senior management will follow the announcement wit
Read more →RIGLRigel Announces Fourth Quarter and Year End 2014 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2014 Financial Results South San Francisco, Calif. March 3, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2014. For the fourth quarter of 2014, Rigel
Read more →RIGLRigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
SOUTH SAN FRANCISCO, Calif. and NEW YORK, February 23, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and Bristol-Myers Squibb Company (NYSE: BMY) today announced that they have entered into a collaboration agreement for the discovery, development and commerciali
Read more →RIGLRigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Jan. 8, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief executive officer, will present updated product development plans and a financial update at the upcoming 33rd Annual
Read more →RIGLRigel to Present at the 33 rd Annual J.P. Morgan Healthcare Conference Earns $5.75M Milestone from AstraZeneca for Asthma Program
Rigel to Present at the 33rd Annual J.P. Morgan Healthcare Conference Earns $5.75M Milestone from AstraZeneca for Asthma Program SOUTH SAN FRANCISCO, Calif. Jan. 8, 2015 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company s president and
Read more →RIGLRigel Announces Executive Management Changes James M. Gower Retires, Raul Rodriguez Named CEO and Appointed to the Board, Gary Lyons Named Chairman
Rigel Announces Executive Management Changes James M. Gower Retires, Raul Rodriguez Named CEO and Appointed to the Board, Gary Lyons Named Chairman SOUTH SAN FRANCISCO, Calif., November 24, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retirin
Read more →RIGLRigel Announces Executive Management Changes
SOUTH SAN FRANCISCO, Calif., Nov. 24, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced James M. Gower is retiring from the board of directors and from his positions as chairman and chief executive officer, and Raul Rodriguez, most recently serving as
Read more →RIGLRigel Announces Third Quarter 2014 Financial Results South San Francisco, Calif.
Rigel Announces Third Quarter 2014 Financial Results South San Francisco, Calif. November 4, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2014. For the third quarter of 2014, Rigel repo
Read more →RIGLR348 Did Not Meet Endpoints in Phase 2 Dry Eye Study Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy
R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study Rigel Reiterates Clinical Focus on Fostamatinib for ITP and IgA Nephropathy SOUTH SAN FRANCISCO, Calif., August 13, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R348, its ophthalmic JAK/SYK inhibitor,
Read more →RIGLRigel Announces Second Quarter 2014 Financial Results
Rigel Announces Second Quarter 2014 Financial Results SOUTH SAN FRANCISCO, Calif. August 5, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2014. For the second quarter of 2014, Rigel reported
Read more →RIGLRigel Initiates Phase 3 Studies of Fostamatinib in ITP
SOUTH SAN FRANCISCO, Calif., July 16, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these
Read more →RIGLRigel to Present at Jefferies 2014 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., May 29, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2014 Global Healthcare Confere
Read more →RIGLRigel Announces First Quarter 2014 Financial Results South San Francisco, Calif.
Rigel Announces First Quarter 2014 Financial Results South San Francisco, Calif. May 7, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2014. For the first quarter of 2014, Rigel reported a net loss of $22.3
Read more →RIGLRigel Announces Webcast of Investor Day on May 6, 2014
SOUTH SAN FRANCISCO, Calif., April 30, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will host an Investor Day on Tuesday, May 6, 2014 from 9:30 a.m. to 12:00 p.m. E.T. in New York City. Rigel management will provide an overview of the co
Read more →RIGLRigel Announces Publication of R118 AMPK Activator Research
SOUTH SAN FRANCISCO, Calif., March 6, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the American Journal of Physiology has published recent research results with its orally-bioavailable AMPK activator, R118. The publication, entitled "Exerci
Read more →RIGLRigel Announces Fourth Quarter and Year End 2013 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2013 Financial Results South San Francisco, Calif. March 4, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2013. For the fourth quarter of 2013, Rigel
Read more →RIGLRigel Announces Participation at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2014 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that company management will present at two upcoming investor conferences. Details of the events are as follows: Cowen and Company 34th Annual Health Care Confer
Read more →RIGLRigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif .
Rigel Will Present Clinical Product Portfolio Update at J.P. Morgan Healthcare Conference Earns $5.75M Milestone from AstraZeneca for Asthma Partnership SOUTH SAN FRANCISCO, Calif., January 10, 2014 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower,
Read more →RIGLRigel to Present at Oppenheimer Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operations officer, is scheduled to present a company overview at the Oppenheimer 24th Annual Healthcare
Read more →RIGLRigel Announces Third Quarter 2013 Financial Results South San Francisco, Calif.
Rigel Announces Third Quarter 2013 Financial Results South San Francisco, Calif. November 5, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2013. For the third quarter of 2013, Rigel repo
Read more →RIGLRigel Provides Pipeline Update
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced updates on two of the Company's pipeline products: R333, a topical dermatological JAK/SYK inhibitor, and fostamatinib, an oral SYK inhibitor. Rigel announced tha
Read more →RIGLRigel to Present at Stifel Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 6, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel 2013 Healthcare Conference in Bo
Read more →RIGLRigel To Focus On ITP, DLE And Dry Eye
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostama
Read more →RIGLRigel s R343 Did Not Meet Primary Endpoint in Asthma Study
Rigel s R343 Did Not Meet Primary Endpoint in Asthma Study SOUTH SAN FRANCISCO, Calif. August 26, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did
Read more →RIGLRigel Announces Second Quarter 2013 Financial Results
Rigel Announces Second Quarter 2013 Financial Results SOUTH SAN FRANCISCO, Calif. August 6, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2013. For the second quarter of 2013, Rigel reported
Read more →RIGLRigel Will Resume Responsibility for Fostamatinib Program
SOUTH SAN FRANCISCO, Calif., June 4, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announced the topline results from OSKIRA-2 and OSKIRA-3, the remaining pivotal Phase 3 clinical trials investigating fostamatinib, the first oral sp
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 Fax: 650.624.1101 http://www.rigel.com Rigel Will Resume Responsibility for Fostamatinib Program Fostamatinib at 100mg BID Significantly Improves Rheu
Rigel Will Resume Responsibility for Fostamatinib Program Fostamatinib at 100mg BID Significantly Improves Rheumatoid Arthritis in Both OSKIRA-2 & OSKIRA-3 SOUTH SAN FRANCISCO, Calif., June 4, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) and AstraZeneca AB (AZ) today announc
Read more →RIGLRigel's R348 to Initiate Phase 2 Clinical Trial in Dry Eye Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a...
SOUTH SAN FRANCISCO, Calif., May 22, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the clinical advancement of three programs in development. The first program is a wholly-owned topical ophthalmic formulation of a JAK/SYK inhibitor, R348, being d
Read more →RIGLRigel Announces First Quarter 2013 Financial Results South San Francisco, Calif.
Rigel Announces First Quarter 2013 Financial Results South San Francisco, Calif. May 7, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6
Read more →RIGLAstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis
AstraZeneca Announces Top-Line Results From OSKIRA-1 Phase 3 Study of Fostamatinib in Rheumatoid Arthritis SOUTH SAN FRANCISCO, Calif., April 5, 2013 AstraZeneca today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the
Read more →RIGLRigel Announces Fourth Quarter and Year End 2012 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2012 Financial Results South San Francisco, Calif. March 5, 2013 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2012. For the fourth quarter of 2012, Rigel
Read more →RIGLRigel to Present at BIO CEO & Investor Conference
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 15th Annual BIO CEO & Investor Conferenc
Read more →RIGLRigel to Focus on Extensive Clinical Pipeline at Upcoming J.P. Morgan Presentation
SOUTH SAN FRANCISCO, Calif., Jan. 3, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, will present an update on the company's product portfolio at the J.P. Morgan Healthcare Co
Read more →RIGLAstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis SOUTH SAN FRANCISCO, Calif. December 13, 2012 AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, th
Read more →RIGLRigel to Present at Jefferies 2012 Global Healthcare Conference in London
SOUTH SAN FRANCISCO, Calif., Nov. 8, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2012 Global Healthcare Confere
Read more →RIGLRigel Announces Third Quarter 2012 Financial Results South San Francisco, Calif.
Rigel Announces Third Quarter 2012 Financial Results South San Francisco, Calif. November 6, 2012 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the three and nine months ended September 30, 2012. For the third quarter of 2012, Rigel reported a n
Read more →RIGLRIGEL ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK South San Francisco, Calif.
RIGEL ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK South San Francisco, Calif., October 3, 2012, Rigel Pharmaceuticals, Inc. (NasdaqGS: RIGL), today announced the pricing of its previously announced underwritten public offering of 13,685,000 shares of its common stock, o
Read more →RIGLRigel to Present at UBS Global Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the UBS Global Life Sciences Conference in
Read more →RIGLRigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibito
Read more →RIGLRigel Announces Second Quarter 2012 Financial Results South San Francisco, Calif.
Rigel Announces Second Quarter 2012 Financial Results South San Francisco, Calif. August 7, 2012 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2012. For the second quarter of 2012, Rigel reported
Read more →RIGLAstraZeneca and Rigel Sign Worldwide License Agreement for a Potential New Treatment for Chronic Asthma
SOUTH SAN FRANCISCO, Calif., June 19, 2012 /PRNewswire/ -- AstraZeneca and Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) today announced an exclusive worldwide license agreement for the global development and commercialization of R256, Rigel's inhaled JAK inhibitor shown to inhibit
Read more →RIGLCERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RIGEL PHARMACEUTICALS, INC. The undersigned hereby certifies that: 1. The original name of this corporation was Rigel Pharmaceuticals, Inc.
CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF RIGEL PHARMACEUTICALS, INC. The undersigned hereby certifies that: 1. The original name of this corporation was Rigel Pharmaceuticals, Inc. and the date of filing the original Certificate of Inc
Read more →RIGLRigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
SOUTH SAN FRANCISCO, Calif., May 16, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc., (Nasdaq: RIGL) is expanding its respiratory franchise by focusing on two innovative, comprehensive treatment alternatives for patients with asthma. One of these agents, R343, an inhaled SYK inh
Read more →RIGLRigel Announces First Quarter 2012 Financial Results South San Francisco, Calif.
Rigel Announces First Quarter 2012 Financial Results South San Francisco, Calif. May 1, 2012 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2012. For the first quarter of 2012, Rigel reported a net loss of $23.2
Read more →RIGLRigel Announces Fourth Quarter and Year End 2011 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2011 Financial Results South San Francisco, Calif. March 6, 2012 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2011. For the fourth quarter of 2011, Rigel
Read more →RIGLRigel Announces Initiation of Clinical Trials in Two Immunology Programs
SOUTH SAN FRANCISCO, Calif., Jan. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (RIGL: Nasdaq) today announced that two of its lead product candidates entered clinical trials during the fourth quarter of 2011. The company is evaluating R548, an oral JAK3 inhibitor, as a pot
Read more →RIGLRigel to Present at Oppenheimer Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 7, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Oppenheimer 22nd Annual Healthcare Conf
Read more →RIGLRigel to Participate at Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., Nov. 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Ryan Maynard, executive vice president and chief financial offer of Rigel, will participate at two i
Read more →RIGLRigel Announces Third Quarter 2011 Financial Results South San Francisco, Calif.
Rigel Announces Third Quarter 2011 Financial Results South San Francisco, Calif. November 1, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2011. For the third quarter of 2011, Rigel rep
Read more →RIGLRigel to Webcast Investor Day on October 13, 2011
SOUTH SAN FRANCISCO, Calif., Oct. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will provide a live webcast of its upcoming Investor/Analyst Day on Thursday, October 13, 2011 at 10:00am EDT. Members of Rigel's senior management team wi
Read more →RIGLRigel Announces Second Quarter 2011 Financial Results South San Francisco, Calif.
Rigel Announces Second Quarter 2011 Financial Results South San Francisco, Calif. August 2, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2011. For the second quarter of 2011, Rigel reported
Read more →RIGLRigel to Present at Wells Fargo Securities Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 16, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul R. Rodriguez, the company's president and chief operating officer, is scheduled to present a company overview at the Wells Fargo Securities 2011 Healthc
Read more →RIGLRigel to Present at Jefferies Global Healthcare Conference
SOUTH SAN FRANCISCO, June 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Jefferies 2011 Global Healthcare Conference in N
Read more →RIGLRigel Announces Pricing of Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 26, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced the pricing of its previously announced underwritten public offering of 16,300,000 shares of its common stock, offered at a price of $8.00 per share to the public
Read more →RIGLRigel Announces Proposed Public Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., May 25, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Rigel. The of
Read more →RIGLRigel Assumes Development Responsibility for Inhaled Asthma Therapy
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc.
Read more →RIGLRigel to Present at Bank of America Merrill Lynch Health Care Conference
SOUTH SAN FRANCISCO, Calif., May 5, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's chief financial officer, is scheduled to present a company overview at the Bank of America Merrill Lynch Health Care Conference in
Read more →RIGLRigel Announces First Quarter Financial Results South San Francisco, Calif.
Rigel Announces First Quarter Financial Results South San Francisco, Calif. May 3, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2011. For the first quarter of 2011, Rigel reported a net loss of $20.8 milli
Read more →RIGLRigel Announces First Quarter Financial Results
SOUTH SAN FRANCISCO, Calif., May 3, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2011. For the first quarter of 2011, Rigel reported a net loss of $20.8 million, or $0.40 per share, compare
Read more →RIGLRigel Announces Fourth Quarter and Year End 2010 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2010 Financial Results South San Francisco, Calif. March 1, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, 2010. For the fourth quarter of 2010, Rigel
Read more →RIGLRigel to Present at Three Upcoming Investor Conferences
SAN FRANCISCO, Feb. 28, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at three investment conferences during the month of March. D
Read more →RIGLRigel to Present at JP Morgan Healthcare Conference
SAN FRANCISCO, Jan. 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the JP Morgan Healthcare Conference in San Francisco, CA o
Read more →RIGLRigel and AstraZeneca Awarded
SOUTH SAN FRANCISCO, Calif., Dec. 9, 2010 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it received the Licensing Deal of the Year award from Scrip Intelligence at the Sixth Annual Scrip Awards last month. The Award, presented jointly to Rigel an
Read more →RIGLRigel to Present at Piper Jaffray Health Care Conference
SOUTH SAN FRANCISCO, Calif., Nov. 23, 2010 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the 22nd Annual Piper Jaffray Hea
Read more →RIGLRigel Announces Third Quarter 2010 Financial Results South San Francisco, Calif.
Announces Third Quarter 2010 Financial Results San Francisco, Calif. November 2, 2010 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2010. the third quarter of 2010, Rigel reported net incom
Read more →RIGLRigel Announces Presentations at Two Investor Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez, president and chief operating officer of Rigel, will present at two separate
Read more →RIGLRigel Earns Milestone Payments From AstraZeneca
SOUTH SAN FRANCISCO, Calif., Sept. 29 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development
Read more →RIGLRigel to Present at Stifel Nicolaus Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 9 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conferen
Read more →RIGLRigel Announces Second Quarter 2010 Financial Results South San Francisco, Calif.
Announces Second Quarter 2010 Financial Results San Francisco, Calif. August 3, 2010 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2010. the second quarter of 2010, Rigel reported a net income o
Read more →RIGLRIGEL PHARMACEUTICALS NAMES RAUL RODRIGUEZ PRESIDENT RYAN MAYNARD AND DOLLY VANCE PROMOTED TO EXECUTIVE VICE PRESIDENTS SOUTH SAN FRANCISCO, Calif., June 1 , 2010 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announce
RIGEL PHARMACEUTICALS NAMES RAUL RODRIGUEZ RYAN MAYNARD AND DOLLY VANCE PROMOTED TO EXECUTIVE SOUTH SAN FRANCISCO, Calif., June 1, 2010 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the promotion of three members of senior management, effective immediately. Raul
Read more →RIGLRigel Announces First Quarter 2010 Financial Results South San Francisco, Calif.
Announces First Quarter 2010 Financial Results San Francisco, Calif. May 4, 2010 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, the first quarter of 2010, Rigel reported a net loss of $22.3 million, or $0.43 pe
Read more →RIGLRigel Announces Fourth Quarter and Year End 2009 Financial Results South San Francisco, Calif.
Rigel Announces Fourth Quarter and Year End 2009 Financial Results South San Francisco, Calif. March 2, 2010 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, For the fourth quarter of 2009, Rigel r
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Announces Third Quarter 2009 Financial Results
Rigel Announces Third Quarter 2009 Financial Results SAN FRANCISCO, Calif., November 3, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30, 2009. the third quarter of 2009, Rigel reported a
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Announces Second Quarter 2009 Financial Results
Rigel Announces Second Quarter 2009 Financial SOUTH SAN FRANCISCO, Calif. August 4, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2009. For the second quarter of 2009, Rigel reported a net
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologi
R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies Results Incongruent Bone MRI Scans Show Improvement; Safety Results Consistent with TASKi2 SAN FRANCISCO, Calif., July 23, 2009 Rigel Pharmaceuticals, In
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel s R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial Expected and Manageable Saf
R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial and Manageable Safety Profile Demonstrated in TASKi2 SOUTH SAN FRANCISCO, Calif., July 9, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R788 (fostamatinib disodium) produced sig
Read more →RIGLRigel Announces First Quarter 2009 Financial Results South San Francisco, Calif.
Announces First Quarter 2009 Financial Results South San Francisco, Calif. May 5, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, 2009. For the first quarter of 2009, Rigel reported a net loss of $29.9 mil
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Announces Fourth Quarter and Year End 2008 Financial Results
Announces Fourth Quarter and Year End 2008 Financial Results SOUTH SAN FRANCISCO, Calif. February 24, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the fourth quarter and year ended December 31, quarter of 2008, Rigel reported a net loss
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results Company Expects Trial Results to Lead to
Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results Company Expects Trial Results to Lead to Enhanced Economics, Trims SAN FRANCISCO, Calif., February 3, 2009 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will delay further partnership d
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Announces Third Quarter 2008 Financial Results and Clinical Update Company to Host Update Conference Call
Rigel Announces Third Quarter 2008 Financial Results Company to Host Update Conference Call Today at 8:30 a.m. EST San Francisco, Calif. November 3, 2008 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the three and nine months ended September 3
Read more →RIGLRigel Announces Second Quarter 2008 Financial Results SOUTH SAN FRANCISCO, Calif., Aug. 5 /PRNewswire-FirstCall/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six
Announces Second Quarter 2008 Financial Results FRANCISCO, Calif., Aug. 5 /PRNewswire-FirstCall/ Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2008. quarter of 2008, Rigel reported a net loss o
Read more →RIGLVeterans Blvd. South San Francisco, CA 94080 Main Phone: 650.624.1100 FAX: 650.624.1101 http://www.rigel.com Rigel Announces First Quarter 2008 Financial Results South San Francisco, Calif.
Rigel Announces First Quarter 2008 Financial Results South San Francisco, Calif. May 6, 2008 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended March 31, During the first quarter of 2008, Rigel reported a net loss of $27.3 m
Read more →RIGLRigel Announces Fourth Quarter and Year End 2007 Financial Results
Rigel Announces Fourth Quarter and Year End 2007 Financial Results SAN FRANCISCO, Calif. February 12, 2008 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2007. quarter of 2007, Rigel reported a n
Read more →RIGLRigel s R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study Achieves Statistically Significant ACR20, ACR50 & ACR70 Results
R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Statistically Significant ACR20, ACR50 & ACR70 Results SOUTH SAN FRANCICSO, Calif., December 13, 2007 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral syk kinase inhibitor, R7
Read more →RIGLRigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study
Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study SOUTH SAN FRANCISCO, Calif., November 9, 2007 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced results of its Phase 2 clinical study of R788, a novel, oral Syk kinase
Read more →RIGLRigel Announces Third Quarter 2007 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 6 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced financial results for the third quarter and nine months ended
Rigel Announces Third Quarter 2007 Financial Results FRANCISCO, Calif., Nov. 6 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced financial results for the third quarter and nine months ended quarter of 2007, Rigel reported a net loss of $18.9 million, or $0.61 per sh
Read more →RIGLRigel Announces Second Quarter 2007 Financial Results
Rigel Announces Second Quarter 2007 Financial Results SAN FRANCISCO, Calif., August 7, 2007 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced financial results for the second quarter and six months ended June 30, 2007. the second quarter of 2007, Rigel reported a net
Read more →RIGLRigel Announces First Quarter 2007 Financial Results South San Francisco, Calif.
First Quarter 2007 Financial Results San Francisco, Calif. May 10, 2007 Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the first quarter ended the first quarter of 2007, Rigel reported a net loss of $17.1 million, or $0.68 per share, compared t
Read more →Competitive Position
How RIGL ranks across every disease it competes inCompetitive Position is a premium feature
See how RIGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial